九州大学 研究者情報
研究者情報 (研究者の方へ)入力に際してお困りですか?
基本情報 研究活動 教育活動 社会活動 病院臨床活動
加藤 聖子(かとう きよこ) データ更新日:2019.08.09

教授 /  医学研究院 臨床医学部門 生殖発達医学


主な研究テーマ
産婦人科における幹細胞研究とその臨床応用
キーワード:幹細胞、婦人科癌、子宮内膜
2012.09~2022.09.
子宮内膜・子宮体癌幹細胞の同定と解析
キーワード:幹細胞
2006.04.
ホルモン依存性腫瘍の発生機構の解明と治療法の開発
キーワード:がん遺伝子、がん抑制遺伝子、ホルモン依存性腫瘍
1992.04.
研究業績
主要著書
1. 加藤 聖子, 今日の治療方針 2018年版 「子宮肉腫」, 60:1315-1316, 2018.01, 悪性軟部腫瘍治療薬としてバゾバニブ(ヴォトリエント)に加えてトラベクテジン(ヨンデリス)、エリブリン(ハラヴェン)が承認を受け、子宮肉腫への治療効果が期待される。.
2. 加藤聖子, rasとそのシグナル, 中山書店, 41,19-42, 2001.01.
3. 加藤聖子、和氣徳夫, 婦人科腫瘍, 中山書店, 看護のための最新医学講座 31 医学と分子生物学 372-378, 2003.01.
4. Kato K and Wake N, Contribution of estrogen receptor α and progesterone receptor-B to oncogenic K-Ras-mediated NIH3T3 cell transformation.:Cell and Molecular Biology of Endometrial Carcinoma, Springer-Verlag Tokyo, 207-218, 2003.01.
主要原著論文
1. Yahata H, Kobayashi H, Sonoda K, Kodama K, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Kaneki E, Okugawa K, Baba S, Isoda T, Ohishi Y, Oda Y, Kato K, Prognostic outcome and complications of sentinel lymph node navigation surgery for early-stage cervical cancer., Int J Clin Oncol, 10.1007/s10147-018-1327-y, 2018.08, BACKGROUND: To evaluate the prognostic outcome and surgical complications in patients with early-stage cervical cancer who underwent sentinel node navigation surgery (SNNS) for hysterectomy or trachelectomy.
METHODS: A total of 139 patients who underwent SNNS using 99mTc phytate between 2009 and 2015 were evaluated. No further lymph node dissection was performed when intraoperative analysis of the sentinel lymph nodes (SLNs) was negative for metastasis. We compared the surgical complications between the SNNS group and 67 matched patients who underwent pelvic lymph node dissection (PLND) after SLN mapping between 2003 and 2008. We also examined the clinical outcomes in the SNNS group.
RESULTS: The mean number of detected SLNs was 2.5 per patient. Fourteen of the 139 patients in the SNNS group underwent PLND based on the intraoperative SLN results. The amount of blood loss, the operative time, and the number of perioperative complications were significantly less in the SNNS group than in the matched PLND group. There was no recurrence during a follow-up period ranging from 2 to 88 months (median 40 months) in the SNNS group.
CONCLUSIONS: Using SNNS for early-stage cervical cancer is safe and effective and does not increase the recurrence rate. A future multicenter trial is warranted..
2. Yasutake N¹, Ohishi Y¹, Taguchi K², Hiraki Y³, Oya M³, Oshiro Y⁴, Mine M⁵, Iwasaki T¹, Yamamoto H¹, Kohashi K¹, Sonoda K⁶, Kato K⁶, Oda Y¹, Insulin-like growth factor II messenger RNA-binding protein-3 is an independ-ent prognostic factor in uterine leiomyosarcoma, Histopathology, 10.1111/his.13422, 72, 5, 739-748, 2018.04, AIMS: The aim of this study was to identify the prognostic factors of uterine leiomyosarcoma (ULMS).
METHODS AND RESULTS: We reviewed 60 cases of surgically resected ULMSs and investigated conventional clinicopathological factors, together with the expression of insulin-like growth factor II messenger RNA-binding protein-3 (IMP3), hormone receptors and cell cycle regulatory markers by immunohistochemistry. Mediator complex subunit 12 (MED12) mutation analysis was also performed. Univariate analyses revealed that advanced stage (P < 0.0001), older age (P = 0.0244) and IMP3 expression (P = 0.0011) were significant predictors of a poor outcome. Multivariate analysis revealed advanced stage (P < 0.0001) and IMP3 (P = 0.0373) as independent predictors of a poor prognosis. Expressions of cell cycle markers and hormone receptors, and MED12 mutations (12% in ULMSs) were not identified as prognostic markers in this study.
CONCLUSIONS: IMP3 expression in ULMS could be a marker of a poor prognosis..
3. Yahata H, Sonoda K, Yasunaga M, Ogami T, Kawano Y, Kaneki E, Okugawa K, Tsunehisa Kaku, Kato K, Surgical treatment and outcome of early invasive adenocarcinoma of the uterine cervix (FIGO stage IA1)., Asia Pac J Clin Oncol 2017, 10.1111/ajco.12691, 14, 2, e50-e53, 2018.04, AIM: To investigate the surgical outcome of FIGO stage IA1 cervical adenocarcinoma.
METHODS: Between 2005 and 2011, 12 patients from Kyushu University Hospital had cervical adenocarcinoma, with a tumor depth of less than 3 mm and a horizontal width of less than 7 mm (FIGO stage IA1), diagnosed by cervical conization. All patients underwent simple hysterectomy or simple trachelectomy with pelvic lymphadenectomy.
RESULTS: The mean patient age was 34 years (range, 26-70 years). The median follow-up period was 70.5 months (range, 26-99 months). No pelvic lymph-node metastasis was seen, and no patient experienced disease recurrence.
CONCLUSION:Early invasive cervical adenocarcinoma with a depth of invasion of 3 mm or less and a horizontal spread of 7 mm or less has little potential for nodal metastasis or recurrence. Therefore, simple hysterectomy or trachelectomy, without lymphadenectomy, might be an alternative treatment option for stage IA1 cervical adenocarcinoma..
4. Ohmaru-Nakanishi T¹, Asanoma K², Fujikawa M¹, Fujita Y¹, Yagi H¹, Onoyama I¹, Hidaka N¹, Sonoda K¹, Kato K¹, Fibrosis in Preeclamptic Placentas Is Associated with Stromal Fibroblasts Acti-vated by the Transforming Growth Factor Beta 1 (TGFB1) Signaling Pathway., Am J Pathol, 10.1016/j.ajpath.2017.11.008, 188, 3, 683-695, 2018.03, Although fibrosis is one of the most prominent pathologic features of preeclamptic (PE) placentas, its mechanism remains largely unknown. Consistent with previous reports, we observed overexpression of collagen; actin, α2, smooth muscle, aorta; connective tissue growth factor; and fibronectin in PE placentas compared with control ones. To investigate the mechanism of fibrosis in PE placentas, placental fibroblasts were isolated from PE placentas or normal pregnancies at delivery. The expression of fibrosis-related factors in fibroblasts was evaluated by real-time RT-PCR, Western blotting, enzyme-linked immunosorbent assay, and gene microarrays. An in vitro collagen gel contraction assay was also performed. Fibroblasts isolated from PE placentas showed higher expression levels of fibrosis-related factors compared with those from control ones. Global gene expression profiling of PE fibroblasts was contrasted with that of control ones and indicated an intimate association with transforming growth factor-β1 (TGF-β1) signaling. Furthermore, the PE fibroblasts expressed abundant phosphorylated SMAD family member 2 and showed higher expression levels of target genes of TGF-β1 signaling compared with the control ones. The PE fibroblasts also had a greater ability to contract compared with the control ones. Contractility also depended on TGF-β1 signaling. Our results suggest that TGF-β1 signaling is activated in the fibroblasts in PE placentas and that these active fibroblasts contribute to fibrosis..
5. Hidaka N , Kido S, Sato Y, Murata M, Fujita Y, Kato K, Thoracoamniotic shunting for fetal pleural effusion with hydropic change using a double-basket catheter: An insight into the preoperative determinants of shunt-ing efficacy., Eur J Obstet Gynecol Reprod Biol, 10.1016/j.ejogrb.2017.12.008, 221, 34-39, 2018.02, OBJECTIVES: Although the efficacy of thoracoamniotic shunting (TAS) for fetal hydrothorax is well-recognized, the coexistence of hydrops fetalis is still a clinical challenge. The preoperative determinants of shunting efficacy are not fully understood. In this study, we aimed to investigate the perinatal and postnatal outcomes of hydrops fetalis with pleural effusion treated by TAS using a double-basket catheter, and to discuss the preoperative factors predictive of patients who will benefit from TAS.

STUDY DESIGN: We conducted a retrospective study in hydropic fetuses with pleural effusion treated by TAS between 2007 and 2015. We extracted information regarding postnatal survival and pretherapeutic sonographic findings, including skin-edema thickness, pleural-effusion pocket size, and Doppler readings.

RESULTS: Twelve subjects underwent TAS at a median gestational age of 29+5 weeks (range, 25+5-33+2 weeks). Skin edema disappeared or regressed in 7. Three experienced early neonatal death and the other 9 ultimately survived after a live birth at a median gestational age of 33+4 weeks (range, 29+1-38+2 weeks). All surviving children, except for 1, had a pretherapeutic pleural-effusion pocket greater than the precordial-edema thickness. All 3 children that died had precordial-edema thickness equal to or greater than the size of the pleural-effusion pocket.

CONCLUSIONS: We achieved a high survival rate (75%) using the double-basket technique. A greater pretherapeutic width of skin edema compared with the pleural-effusion pocket is possibly suggestive of a treatment-resistant condition and subsequent poor postnatal outcome..
6. Sonoda K¹, Yahata H, Okugawa K, Kaneki E, Ohgami T, Yasunaga M, Baba S, Oda Y, Honda H, Kato K, Value of Intraoperative Cytological and Pathological Sentinel Lymph Node Di-agnosis in Fertility-Sparing Trachelectomy for Early-Stage Cervical Cancer, Oncology, 10.1159/000484049, 94, 2, 92-98, 2018.02, BACKGROUND AND OBJECTIVES: Trachelectomy, a fertility-sparing surgery for early-stage cervical cancer, can be performed only when there is no extrauterine extension present. Therefore, identifying the sentinel lymph nodes (SLNs) and using them to obtain an intraoperative pathologic diagnosis can provide information on the feasibility and safety of trachelectomy. Our aim was to assess the value of an intraoperative SLN diagnosis.
METHODS: We retrospectively analyzed the accuracy of intraoperative imprint cytology and frozen-section examination in 201 patients at our institution in whom trachelectomy was planned.
RESULTS: All patients could be evaluated for SLNs; a total of 610 SLNs were analyzed. Although the specificity of both imprint cytology and frozen-section examination was 100.0%, the sensitivity was only 58.6 and 65.5%, respectively. The diagnostic sensitivity was higher in 2-mm slices along the short axis than on bisection along the longitudinal axis. Imprint cytology correctly diagnosed 2 patients who had false-negative results on frozen section. The nature of the metastatic foci that caused an intraoperative false-negative diagnosis was either micrometastasis or isolated tumor cells.
CONCLUSIONS: The accuracy of intraoperative SLN diagnosis requires improvement, especially when small metastatic foci are present..
7. Morokuma S, Michikawa T, Yamazaki S, Nitta H, Kato K, Association between exposure to air pollution during pregnancy and false posi-tives in fetal heart rate monitoring., Scientific reports, 10.1038/s41598-017-12663-2, 7, 1, 1-8, 2017.09, Fetal heart rate (FHR) monitoring is essential for fetal management during pregnancy and delivery but results in many false-positive diagnoses. Air pollution affects the uterine environment; thus, air pollution may change FHR reactivity. This study assessed the association between exposure to air pollution during pregnancy and FHR monitoring abnormalities using 2005-2010 data from the Japan Perinatal Registry Network database. Participants were 23,782 singleton pregnant women with FHR monitoring, without acidemia or fetal asphyxia. We assessed exposure to air pollutants, including particulate matter (PM), ozone, nitrogen dioxide (NO2), and sulfur dioxide (SO2). In a multi-trimester model, first-trimester PM exposure was associated with false positives in FHR monitoring (odds ratio [OR] per interquartile range (10.7 μg/m3) increase = 1.20; 95% CI: 1.05-1.37), but not second-trimester exposure (OR = 1.05; 95% CI: 0.91-1.21) and third-trimester exposure (OR = 1.06; 95% CI: 0.96-1.17). The association with first-trimester PM exposure persisted after adjustment for exposure to ozone, NO2, and SO2; however, ozone, NO2, and SO2 exposure was not associated with false positives in FHR monitoring. First-trimester PM exposure may alter fetal cardiac response and lead to false positives in FHR monitoring..
8. Kido S, Hidaka N, Sato Y, Fujita Y, Miyoshi K, Nagata K, Taguchi T, Kato K, Re-evaluation of lung to thorax transverse area ratio immediately before birth in predicting postnatal short-term outcomes of fetuses with isolated left-sided congenital diaphragmatic hernia: a single center analysis., Congenit Anom (Kyoto), 10.1111/cga.12243, 1-6, 2017.08, We aimed to investigate whether the lung-to-thorax transverse area ratio (LTR) immediately before birth is of diagnostic value for the prediction of postnatal short-term outcomes in cases of isolated left-sided congenital diaphragmatic hernia (CDH). We retrospectively reviewed the cases of fetal isolated left-sided CDH managed at our institution between April 2008 and July 2016. We divided the patients into two groups based on LTR immediately before birth, using a cut-off value of 0.08. We compared the proportions of subjects within the two groups who survived until discharge using Fisher's exact test. Further, using Spearman's rank correlation, we assessed whether LTR was correlated with length of stay, duration of mechanical ventilation, and supplemental oxygen. Twenty-nine subjects were included (five with LTR < 0.08, and 24 with LTR ≥ 0.08). The proportion of subjects surviving until discharge was 40% (2/5) for patients with LTR < 0.08, as compared with 96% (23/24) for those with LTR ≥ 0.08. LTR measured immediately before birth was negatively correlated with the postnatal length of stay (Spearman's rank correlation coefficient, rs = -0.486), and the duration of supplemental oxygen (rs = -0.537). Further, the duration of mechanical ventilation was longer in patients with a lower LTR value. LTR immediately before birth is useful for the prediction of postnatal short-term outcomes in fetuses with isolated left-sided CDH. In particular, patients with prenatal LTR value less than 0.08 are at increased risk of postnatal death..
9. Okawa H, Morokuma S, Maehara K, Arata A, Ohmura Y, Horinouchi T, Konishi Y, Kato K, Eye movement activity in normal human fetuses between 24 and 39 weeks of gestation., PLos One, 10.1371/journal.pone.0178722, 12, 7, 1-12, 2017.07, Rapid eye movement (REM) sleep occurs throughout a relatively large proportion of early development, and normal REM activity appears to be required for healthy brain development. The eye movements (EMs) observed during REM sleep are the most distinctive characteristics of this state. EMs are used as an index of neurological function postnatally, but no specific indices of EM activity exist for fetuses. We aimed to identify and characterize EM activity, particularly EM bursts suggestive of REM periods, in fetuses with a gestational age between 24 and 39 weeks. This cross-sectional study included 84 normal singleton pregnancies. Fetal EMs were monitored using real-time ultrasonography for 60 min and recorded as videos. The videos were manually converted into a time series of EM events, which were then analyzed by piecewise linear regression for various EM characteristics, including EM density, EM burst density, density of EMs in EM bursts, and continuous EM burst time. Two critical points for EM density, EM burst density, and density of EMs in EM bursts were evident at gestation weeks 28-29 and 36-37. Overall EM activity in human fetuses increased until 28-29 weeks of gestation, then again from 36-37 to 38-39 weeks of gestation. These findings may be useful for creating indices of fetal neurological function for prognostic purposes..
10. Okugawa K, Kobayashi H, Sonoda K, Kaneki E, Kawano Y, Hidaka N, Egashira K, Fujita Y, Yahata H, Kato K, Oncologic and obstetric outcomes and complications during pregnancy after fertility-sparing abdominal trachelectomy for cervical cancer:a retrospective review.
, Int J Oncol, 10.1007/s10147-016-1059-9, 22, 2, 340-346, 2017.04, BACKGROUND: Trachelectomy was developed as a fertility-sparing surgery for early-stage cervical cancer in patients of childbearing age. The purpose of this study is to evaluate oncologic and obstetric outcomes and complications after abdominal trachelectomy.

METHODS: We began to perform abdominal trachelectomy in 2005. Our institutional review board approved this clinical study, and fully informed consent was obtained from each patient. The medical records of patients who underwent trachelectomy were retrospectively reviewed.

RESULTS: We performed 151 abdominal trachelectomies (89 radical trachelectomies, 48 modified radical trachelectomies, and 14 simple trachelectomies). The median age of the patients was 33 years, and the median postoperative follow-up period was 61 months. Although one patient experienced recurrence at the preserved cervix, none died after treatment. A total of 61 patients attempted to conceive after trachelectomy, and 21 pregnancies were achieved in 15 women. Hence, the pregnancy rate among patients who attempted to conceive was 25%. Fifteen babies were delivered by cesarean section between gestational weeks 23 and 37. Six babies were delivered at term. Six cases of preterm premature rupture of the membranes occurred. Varices appeared around the uterovaginal anastomotic site in five patients.

CONCLUSIONS: Our data indicate that the oncologic outcome was excellent but infertility treatment was necessary to achieve the majority of conceptions. Additionally, preterm premature rupture of the membranes and premature delivery were frequently observed. An improved pregnancy rate and prevention of complications during pregnancy are issues that should be addressed in future studies.
.
11. Morokuma S, Tsukimori K, Hori T, Kato K, Furue M, The Vernix Caseosa is the Main Site of Dioxin Excretion in the Human Foetus., Sci Rep, 10.1038/s41598-017-00863-9, 7, 1, 739-739, 2017.04, Dioxins are highly toxic to foetuses and prenatal exposure leads to adverse health effects; however, the metabolic pathways involved in dioxin excretion are poorly understood. We determined the dynamics of maternal-to-foetal dioxin transfer during normal pregnancy and how foetuses eliminate polychlorinated dibenzo-p-dioxins, polychlorinated dibenzofurans, and non-ortho polychlorinated biphenyls. Dioxin levels in maternal blood, cord blood, placenta, vernix caseosa, meconium, and amniotic fluid were analysed by high-resolution gas chromatography/mass spectrometry. The average levels of total dioxins, expressed as picograms of toxic equivalency quantity per gram of lipid and in parentheses, dioxin fraction, with maternal blood levels arbitrarily set as 100%, were as follows: maternal blood, 15.8 (100%); placenta, 12.9 (81.5%); cord blood, 5.9 (37.2%); vernix caseosa, 8.4 (53.2%); meconium, 2.9 (18.2%); and amniotic fluid, 1.5 (9.2%). Similar proportions were observed for each dioxin congener. Thus, the highest content of foetal dioxins was observed in the vernix caseosa, indicating that this is the major site of dioxin excretion in human foetuses..
12. Kitade S, Onoyama I, Kobayashi H, Yagi H, Kato M, Tsunematsu R, Asanoma K, Sonoda K, Wake N, Hata K, Nakayama K, Kato K, FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian Tumors., Cancer Sci, 10.1111/cas.13026., Epub ahead of print, 2016.08, FBXW7 is a ubiquitin ligase that mediates ubiquitylation of oncoproteins, such as c-Myc, cyclin E, Notch and
c-Jun. FBXW7 is a known tumor-suppressor gene, and mutations in FBXW7 have been reported in various
human malignancies. In this study, we examined the sequences of the FBXW7 and p53 genes in 57 ovarian
cancer clinical samples. Interestingly, we found no FBXW7 mutations associated with amino acid changes.
We also investigated FBXW7 expression levels in 126 epithelial ovarian tumors. FBXW7 expression was
negatively correlated with the malignant potential of ovarian tumors. That is to say, FBXW7 expression
levels in ovarian cancer samples were significantly lower than those in borderline and benign tumors
(P < 0.01). FBXW7 expression levels in serous carcinoma samples were the lowest among four major
histological subtypes. In addition, p53-mutated ovarian cancer samples showed significantly lower levels
of FBXW7 expression compared with p53 wild-type cancer samples (P < 0.001). DNA methylation arrays
and bisulfite PCR sequencing experiments revealed that 5'-upstream regions of FBXW7 gene in p53-mutated
samples were significantly higher methylated compared with those in p53 wild-type samples (P < 0.01).
This data indicates that p53 mutations might suppress FBXW7 expression through DNA hypermethylation
of FBXW7 5'-upstream regions. Thus, FBXW7 expression was downregulated in ovarian cancers, and was
associated with p53 mutations and the DNA methylation status of the 5'-upstream regions of FBXW7..
13. 川上 穣, 日高 庸博, 原 枝美子, 佐藤 由佳, 近藤 有希子, 村田 将春, 藤田 恭之, 加藤 聖子, 母体CMV-IgMが陰性であった先天性サイトメガロウイルス感染症の1例., 超音波医学, 10.3179/jjmu. JJMU.A.59, 43, 3, 505-508, 2016.06, 妊娠中のサイトメガロウイルス(CMV)感染は児に不良な予後をもたらしうる重大な感染症であり,診断には母体の血清CMV-IgMが
用いられることが多い.症例は29歳の初産婦.妊娠24週の超音波検査で胎児の発育不全,腹水,腸管高輝度像を認めた.
胎児中大脳動脈最高血流速度が2.5 MoMと高値であり臍帯穿刺を行ったが,臍帯血の血色素量は9.2 g/dlと貧血は軽度で,一方で
血小板数が2.8万/μlと著明低値であった.母体血清よりTORCHスクリーニングを行ったが,CMV-IgMをはじめ全て陰性であった.
しかし諸所見からCMV感染を強く疑い,羊水でのCMV-PCR検査を行ったところ,陽性であり先天感染の診断に至った.
妊娠26週に胎児機能不全と診断したが急速墜娩を選択されず,子宮内胎児死亡となった.死産後の胎盤病理検査で巨細胞封入体を認め,免疫染色で抗CMV抗体が陽性であった.先天性CMV感染は母体のCMV-IgMが陰性であることをもって必ずしも否定されず,
諸所見で感染を強く疑えば羊水PCR検査を考慮すべきである..
14. Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ogami T, Saito T, Ogawa S, Sakai K, Ichinoe A, Ueoka Y, Hasuo Y, Nishida M, Masuda S, Kato K, Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately
emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in
patients with gynecologic cancer receiving paclitaxel and carboplatin., Int J Clin Oncol, 10.1007/s10147-015-0928-y., 21, 3, 491-497, 2016.06, BACKGROUND: Substance P contributes to the hypersensitivity reaction (HSR) to paclitaxel in a rat model.
Aprepitant acts as an inhibitor of the binding of substance P to the neurokinin-1 receptor and, consequently,
may reduce the frequency of paclitaxel-induced HSR. While aprepitant has a prophylactic effect against
vomiting caused by high-dose cisplatin, the benefits of aprepitant have not been clearly demonstrated in
patients receiving paclitaxel and carboplatin (TC) combination chemotherapy.

METHODS: We conducted a multicenter, placebo-controlled, double-blind, randomized study in Japanese
patients with gynecologic cancer who received TC combination chemotherapy. Patients received aprepitant
or placebo together with both a 5-HT3 receptor antagonist and dexamethasone prior to chemotherapy.
The primary endpoint was the proportion of patients with HSR, and the secondary endpoints were the
proportion of patients with "no vomiting", "no significant nausea", and complete response, respectively.

RESULTS: Of the 324 randomized patients, 297 (151 in the aprepitant group; 146 in the placebo group)
were evaluated. The percentage of patients with HSR (9.2 vs. 7.5 %, respectively; P = 0.339) was not
significantly different between the groups. The percentage of "no vomiting" patients (78.2 vs. 54.8 %;
P < 0.0001), "no significant nausea" patients (85.4 vs. 74.7 %; P = 0.014), and patients showing complete
response (61.6 vs. 47.3 %, P = 0.0073) was significantly higher in the aprepitant group than in the placebo
group.

CONCLUSION: The administration of aprepitant did not have a prophylactic effect on the HSR but was
effective in reducing nausea and vomiting in gynecologic cancer patients receiving TC combination
chemotherapy..
15. 村上 健太, 日高 庸博, 村田 将春, 藤田 恭之, 加藤 聖子, 500g未満で出生した胎児発育不全例の出生前経過と生後予後, 日本周産期・新生児医学会雑誌, 52, 1, 64-70, 2016.05, 2006年1月から2015年2月までに当科で胎児発育不全と診断し妊娠22週以降に500g未満で出生となった単胎症例を対象とし, 診療録から後方視的に検討した. 形態異常児は除外した. 対象は17例で, 児出生体重の中央値は404g(267-496g), 分娩週数の中央値は妊娠26週2日(妊娠24週0日-妊娠29週2日)で, すべて帝王切開分娩となっていた. 7例(41%)が高血圧または妊娠高血圧症候群を合併し, 11例(64%)に羊水過少, 全例に血流再分配像, 14例(82%)に臍帯動脈の拡張期途絶逆流現象を認めていた. 児は11例(65%)が生存退院し, 1例が精神発達遅滞, 1例が脳性麻痺と診断されていた. 生存退院率は低くなく, 重篤な発達障害をきたしたものも少数であった. 24週, 300gというラインは相応の予後が見込める水準と考えられ, 早期発症の胎児発育不全を管理するにあたって, 児救命を目指した産科管理を適用することが原則になって良いと考えられた..
16. Masuda A, Katoh N, Nakabayashi K, Kato K, Sonoda K, Kitade M, Takeda S, Hata K, Tomikawa J, An improved method for isolation of epithelial and stromal cells from the human endometrium., The Journal of reproduction and development, 10.1262/jrd.2015-137, 62, 2, 213-218, 2016.04, We aimed to improve the efficiency of isolating endometrial epithelial and stromal cells (EMECs and EMSCs) from the human endometrium. We revealed by immunohistochemical staining that the large tissue fragments remaining after collagenase treatment, which are usually discarded after the first filtration in the conventional protocol, consisted of glandular epithelial and stromal cells. Therefore, we established protease treatment and cell suspension conditions to dissociate single cells from the tissue fragments and isolated epithelial (EPCAM-positive) and stromal (CD13-positive) cells by fluorescence-activated cell sorting. Four independent experiments showed that, on average, 1.2 × 10(6) of EMECs and 2.8 × 10(6) EMSCs were isolated from one hysterectomy specimen. We confirmed that the isolated cells presented transcriptomic features highly similar to those of epithelial and stromal cells obtained by the conventional method. Our improved protocol facilitates future studies to better understand the molecular mechanisms underlying the dynamic changes of the endometrium during the menstrual cycle..
17. Yagi H, Asanoma K, Ohgami T, Ichinoe A, Sonoda K, Kato K, GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer., Oncogene, 10.1038/onc.2015.505., 2016.01, G-protein-coupled receptors (GPCRs) and their ligands function in the progression of human malignancies. Gα12 and Gα13, encoded by GNA12 and GNA13, respectively, are referred to as the GEP oncogene and are implicated in tumor progression. However, the molecular mechanisms by which Gα12/13 activation promotes cancer progression are not fully elucidated. Here, we demonstrate elevated expression of Gα12/13 in human ovarian cancer tissues. Gα12/13 activation did not promote cellular migration in the ovarian cancer cell lines examined. Rather, Gα12/13 activation promoted cell growth. We used a synthetic biology approach using chimeric G proteins and GPCRs activated solely by artificial ligands to selectively trigger signaling pathways downstream of specific G proteins. We found that Gα12/13 promotes proliferation of ovarian cancer cells by activating the transcriptional coactivator YAP, a critical component of the Hippo signaling pathway. Furthermore, we reveal that inhibition of YAP by short hairpin RNA or a specific inhibitor prevented the growth of ovarian cancer cells. Therefore, YAP may be a suitable therapeutic target in ovarian cancer.Oncogene advance online publication, 25 January 2016; doi:10.1038/onc.2015.505..
18. Inagaki T, Kusunoki S, Tabu K, Okabe H, Yamada I, Taga T, Matsumoto A, Makino S, Takeda S, Kato K, Up-regulation of lymphocyte antigen 6 complex expression in side-population cells de-rived from a human trophoblast cell line HTR-8/SVneo., Human Cell, 10.1007/s13577-015-0121-7, 29, 1, 10-21, 2016.01, The continual proliferation and differentiation of trophoblasts are critical for the maintenance of pregnancy. It is well known that the tissue stem cells are associated with the development of tissues and pathologies. It has been demonstrated that side-population (SP) cells identified by fluorescence-activated cell sorting (FACS) are enriched with stem cells. The SP cells in HTR-8/SVneo cells derived from human primary trophoblast cells were isolated by FACS. HTR-8/SVneo-SP cell cultures generated both SP and non-SP (NSP) subpopulations. In contrast, NSP cell cultures produced NSP cells and failed to produce SP cells. These SP cells showed self-renewal capability by serial colony-forming assay. Microarray expression analysis using a set of HTR-8/SVneo-SP and -NSP cells revealed that SP cells overexpressed several stemness genes including caudal type homeobox2 (CDX2) and bone morphogenic proteins (BMPs), and lymphocyte antigen 6 complex locus D (LY6D) gene was the most highly up-regulated in HTR-8/SVneo-SP cells. LY6D gene reduced its expression in the course of a 7-day cultivation in differentiation medium. SP cells tended to reduce its fraction by treatment of LY6D siRNA indicating that LY6D had potential to maintain cell proliferation of HTR-8/SVneo-SP cells. On ontology analysis, epithelial-mesenchymal transition (EMT) pathway was involved in the up-regulated genes on microarray analysis. HTR-SVneo-SP cells showed enhanced migration. This is the first report that LY6D was important for the maintenance of HTR-8/SVneo-SP cells. EMT was associated with the phenotype of these SP cells..
19. Satoru Kyo, Kiyoko Kato, Endometrial Cancer Stem Cell as a Potential Therapeutic Target., Semin Reprod Med, 33, 5, 341-349, 2015.09, Adult stem cells have recently been identified in several types of mature tissue and it has been also suggested that stem-like cells exist in cancerous tissues. It is believed that many cancer stem cells (CSCs) upregulate the expression of drug transporters, allowing them to efficiently pump antitumor agents out of the cells. CSCs reside in a quiescent state, making them resistant to chemotherapeutic agents that target rapidly cycling cells. They are also endowed with a more invasive and metastatic phenotype. These results indicate the requirement to develop a new target treatment for CSCs. There are several methods for the identification of CSCs; for example, detection by CSC markers, such as CD133, CD44, CD117(c-kit), aldehyde dehydrogenase 1 (ALDH1), and isolation of side population (SP), which are identified based on their ability to remove intracellular Hoechst 33342, a fluorescent dye. Here, we review recent articles that show the presence of stem cells in endometrial cancer and introduce the results of our own recent studies using CD133 or CD117 positive cells and SP cells..
20. Kanako Okamoto, Ryosuke TSUNEMATSU, Tomoko Tahira, Kenzo Sonoda, KAZUO ASANOMA, Hiroshi Yagi, Tomoko Yoneda, Kenshi Hayashi, Norio Wake, Kiyoko Kato, SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers, BMC MEDICAL GENETICS, 10.1186/s12881-015-0216-8, 16, 1, 67, 2015.08, BACKGROUND:
The functional single nucleotide polymorphism (SNP) in the MDM2 promoter region, SNP309, is known to be associated with various diseases, particularly cancer. Although many studies have been performed to demonstrate the mechanism of allele-specific expression (ASE) on SNP309, they have only utilized in vitro techniques. It is unknown whether ASE of MDM2 is ascribed solely to SNP309, in vivo.

METHODS:
We attempted to evaluate ASE of MDM2 in vivo using post-labeling followed by automated capillary electrophoresis under single-strand conformation polymorphism conditions. For measuring a quantitative difference, we utilized the SNPs on the exons of MDM2 as markers, the status of which was heterozygous in a large population. To address the cause of ASE beyond 20 %, we confirmed sequences of both MDM2-3'UTR and promoter regions. We assessed the SNP which might be the cause of ASE using biomolecular interaction analysis and luciferase assay.

RESULTS:
ASE beyond 20 % was detected in endometrial cancers, but not in cancer-free endometria samples only when an SNP rs1690916 was used as a marker. We suspected that this ASE in endometrial cancer was caused by the sequence heterogeneity in the MDM2-P2 promoter, and found a new functional polymorphism, which we labelled SNP55. There was no difference between cancer-free endometria and endometrial cancer samples neither for SNP55 genotype frequencies nor allele frequencies, and so, SNP55 alone does not affect endometrial cancer risk. The SNP55 status affected the DNA binding affinity of transcription factor Sp1 and nuclear factor kappa-B (NFκB). Transcriptional activity of the P2 promoter containing SNP55C was suppressed by NFκB p50 homodimers, but that of SNP55T was not. Only ASE-positive endometrial cancer samples displayed nuclear localization of NFκB p50.

CONCLUSIONS:
Our findings suggest that both the SNP55 status and the NFκB p50 activity are important in the transcriptional regulation of MDM2 in endometrial cancers..
21. Hitomi Okabe, Shintaro Makino, Kiyoko Kato, Kikumi Matsuoka, Hioyuki Seki, Satoru Takeda, The effect of progesterone on genes involved in preterm labor. , J Reprod Immunol, 10.1016/j.jri.2014.03.008, 104-105, 80-91, 2014.10, The decidua is known to be a major source of intrauterine PGF2α during late gestation and labor, and inflammatory cytokines, including IL-1β, IL-6, and IL-8, are elevated in spontaneous preterm deliveries. In the present study, to elucidate how progesterone blocks the pathways associated with preterm birth, we determined the effects of P4 on the expression of PTGS-2 and PTGFR mRNA in human decidua fibroblast cells, as well as the genes, using microarray analysis. Senescence was induced in primary cultured human decidual cells treated with IL-1β. The IL-1β treatment implicated by microarray analysis increased gene expression levels of PTGS-2, PTGFR, NFκ-B p65, IL-17, and IL-8. In contrast, P4+IL-1β decreased the expression levels of all of these genes in comparison to treatment with IL-1β alone (p<0.05). IL-1β also increased the proportion of SA-β-gal-positive cells. Treatment with IL-1β also increased the p21 protein level in comparison to cells treated either with the vehicle or P4. Neither the p21 protein level nor the number of SA-β-gal-positive cells was increased in normal endometrial glandular cells by IL-1β (p<0.05). Our studies demonstrated that P4 changes the level of gene expression in a manner that favors an anti-inflammatory milieu. Because IL-8 appears to be the cytokine whose expression is most significantly modulated by P4, further studies evaluating IL-8 as a therapeutic target are needed. .
22. Nurismangul Yusuf, Tetsunori Inagaki, Soshi Kusunoki, Hitomi Okabe, Izumi Yamada, Akemi Matsumoto, Yasuhisa Terao, Satoru Takeda, Kiyoko Kato, SPARC was overexpressed in human endometrial cancer stem-like cells and promoted migration activity.
, Gynecologic Oncology, 134, 2, 356-363, 2014.08, Objectives
We previously demonstrated that side-population (SP) cells found in human endometrial cancer tissue have features of cancer stem cells (CSCs). Endometrial cancer SP cells show enhanced migration, the potential to differentiate into the mesenchymal cell lineage, and they are associated with the epithelial–mesenchymal transition (EMT). In this study, we analyzed the expression and function of a specific protein, SPARC (secreted protein acidic and rich in cysteine) which we found to be up-regulated in endometrial cancer.

Methods
We performed microarray expression analysis to screen for up-regulated genes in CSCs using a set of RK12V-SP cells and -non-SP (NSP) cells. We used the MetaCore package to identify the Gene GO pathway MAPs associated with the up-regulated genes. Here, we investigated the expression and functions of SPARC, one of the genes up-regulated in endometrial CSCs.

We established SPARC-overexpressing cells by transfecting endometrial cancer cells (Ishikawa cells [IK-SPARC cells]). We characterized these cells' growth rate, tumorigenicity, migration and invasion activity. The levels and locations of SPARC protein expression in Hec1SP cells-derived tumors and endometrial cancer tissues were examined by immunohistochemistry.

Results
SPARC was detected by microarray expression analysis during screens for up-regulated genes in SP and NSP CSC. The level of SPARC expression was enhanced in Hec1 SP cells compared with that in Hec1 non-SP cells. SPARC enhanced fibronectin expression and promoted migration activity in IK cells. SPARC expression suppressed tumor growth but promoted formation of tumor stroma.

SPARC was expressed in endometrial cancer tissues, in particular, poorly differentiated endometrioid adenocarcinoma, clear and serous adenocarcinoma,but not in normal endometrial tissue.

Conclusion
This is the first report of overexpression of SPARC in endometrial cancer stem-like cells. SPARC expression is associated with cell migration and stroma formation.

Keywords
SPARC; Endometrial cancer; EMT; CSCs; Cell migration
.
23. Soshi Kusunoki, Kiyoko Kato, Kouichi Tabu, Tetsunori Inagaki, Hitomi Okabe, Hiroshi Kaneda, Shin Suga, Yasuhisa Terao, Tetsuya Taga, Satoru Takeda, The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial cancer stem-like cells, GYNECOLOGIC ONCOLOGY, 10.1016/j.ygyno.2013.03.005, 129, 3, 598-605, 2013.06, Goals: We previously demonstrated that side-population (SP) cells in human endometrial cancer cells (Hec1 cells) and in rat endometrial cells expressing oncogenic human K-Ras protein (RK12V cells) have features of cancer stem cells (CSCs). Hec1-SP cells showed enhanced migration and
the potential to differentiate into the mesenchymal cell lineage. In this study, we analyzed the association of the epithelial-mesenchymal transition (EMT) with the properties of these endometrial CSCs. We also assessed and the effects of salinomycin (a compound with EMT-specific toxicity) on the proliferative capacity, migration and invasiveness of these endometrial CSCs using Hec1-SP cells.
Method: We performed microarray expression analysis to screen for up-regulated genes in CSCs using a set of RK12V-SP cells and –non-SP(NSP) cells and used the Metacore package to identify the Gene GO pathway MAPs involved in the up-regulated genes. To analyze their association with EMT, the expression of several EMT associated genes in Hec1-SP cells was investigated by real time PCR and compared with that in Hec1-NSP cells. We assessed the expression of BAX, BCL2, LEF1, cyclinD and fibronectin by real time PCR. We also evaluated the viabilities, migration and invasive activities, and tumorigenicities of these SP cells and NSP cells in the presence or absence of salinomycin.
Results: We demonstrated that i) EMT processes were observed in both RK12V-SP cells and Hec1-SP cells, ii) the level of fibronectin was enhanced in Hec1-SP cells and salinomycin reduced the level of fibronectin expression, iii) salinomycin induced apoptosis and inhibited Wnt signaling, and iv) salinomycin inhibited the proliferation, migration, invasiveness and tumorigenicity of these SP cells.
Conclusion: This is the first report of an inhibitory effect of salinomycin on the properties of endometrial CSCs..
24. Tomoko Yoneda, Ayumi Kuboyama, Kiyoko Kato, Tatsuhiro Ogami, Kanako Okamoto, Toshiaki Saito, Norio Wake, Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer, ONCOLOGY REPORTS, 10.3892/or.2013.2433, 30, 1, 25-34, 2013.07.
25. Kato K, Kuhara A, Yoneda T, Inoue T, Takao T, Ohgami T, Dan L, Kuboyama A, Kusunoki S, Takeda S, Wake N: , Sodium Butyrate inhibitis the Self-Renewal Capacity of Endometrial Tumor Side-Population Cells by Induction a DNA Damage Response.
, Mol Cancer Ther.
, 10, 8, 1-10, 2011.09.
26. Kato K, Takao T, Kuboyama A, Tanaka Y, Ohgami T, Yamaguchi S, Adachi S, Yoneda T, Ueoka Y, Kato K, Hayashi S, Asanoma K, Wake N: , Endometrial cancer side-population cells show prominent migration and have a potential to differentiate into the mesenchymal cell lineage. , Am J Pathol., 176, 1, 381-392, 2010.01.
27. Inoue T, Kato K, Kato H, Asanoma K, Kuboyama A, Ueoka Y, Yamaguchi S, Ohgami T, Wake N, Level of reactive oxygen species induced by p21Waf1/CIP1 is critical for the determination of cell fate. , Cancer Sci., 100, 7, 1275-1283, 2009.07.
28. Takahashi A, Kato K, Kuboyama A, Inoue T, Tanaka Y, Kuhara A, Kinoshita K, Takeda S, Wake N, Induction of senescence by progesterone receptor-B activation in response to cAMP in ovarian cancer cells. , Gynecol Oncol., 113, 2, 270-276, 2009.02.
29. Tanaka Y, Wake N, Kato K, Letter to Editor, Menopause, in press, 2009.05.
30. Inoue T, Kato K, Kato H, Asanoma K, Kuboyama A, Oogami T, Ueoka Y, Wake N, The level of reactive oxygen species induced by p21 WAF1/CIP1 is critical the determination of cell
fate
, Cancer Sci, in press, 2009.05.
31. Takahashi A, Kato K, Kuboyama A, Inoue T, Tanaka Y, Kuhara A, Kinoshita K, Takeda S, Wake N, Induction of senescence by progesterone receptor –B activation in response to cAMP in ovarian cancer
cells
, Gynecol Oncol, 113:270-276, 2009.05.
32. Tanaka Y , Kato K , Mibu R , Uchida S , Asanoma K , Hashimoto K , Nozaki M , Wake N, Medroxyprogesterone acetate inhibits proliferation of colon cancer cell lines by modulating cell
cycle-related protein expression
, Menopause, 15:442-453, 2008.05.
33. Kato K, Yoshimoto M, Kato K, Adachi S, Yamayoshi A, Arima T, Asanoma K, Kyo S, Nakahata T, Wake N, Characterization of side population cells (SP cells) in human normal endometrial cells
, Human Reproduction, 22:1214-23, 2007.04.
34. Ninomiya Y, Kato K, Takahashi A, Ueoka K, Kamikihara T, Arima T, Matsuda T,Kato H, Nishida J, Wake N,, K-Ras and H-Ras activation promote distinct consequences on endometrial cell survival., Cancer Research, 10.1158/0008-5472.CAN-3487-2, 64, 8, 2759-2765, 64, 2759-2765, 2004.04.
主要総説, 論評, 解説, 書評, 報告書等
1. 加藤聖子, 性器の形態異常, 日本医事新報. 4966: 54-5, 2019.06, 胎生7週以降,Y染色体を持たない未分化生殖腺が卵巣に分化し,それに引き続き,胎生体腔上皮由来のミュラー管が発達し,胎生11週には,左右のミュラー管が癒合し,子宮と腟の上1/3に,融合しなかった部分は卵管に分化する。腟下部,尿道,膀胱は尿生殖洞から,小陰唇は総排泄腔ヒダから分化する。性器の形態異常はこの分化過程の異常である。
①頻度の高いものとして,尿生殖洞の分化異常により処女膜が開口していない処女膜閉鎖,ミュラー管の癒合不全である子宮・腟中隔,②比較的稀なものとして,ミュラー管の発生異常で子宮・腟を欠損しているMayer-Rokitansky-Küster-Hauser(MRKH)症候群,子宮頸部の無あるいは低形成,③希少疾患である尿直腸中隔の形成異常による総排泄腔遺残症,④先天性副腎過形成や後天的には副腎腫瘍により発生し,陰核が肥大する副腎性器症候群,⑤46XYの核型で,多くはアンドロゲン受容体の遺伝子異常によるアンドロゲン不応症,などがある。.
2. 矢幡秀昭、権丈洋徳、加藤聖子, 広汎子宮全摘出術の実際-九州大学, 産科と婦人科. 86(6):753-7, 2019.06, 広汎子宮全摘術は婦人科腫瘍医にとって1つの目標であり、婦人科腫瘍専門医取得のためにも15例の執刀が義務づけられている。九州大学でも諸先輩方の術式を伝承しつつも、パワーデバイスを中心とした手術器具の進歩やセンチネルリンパ節生検による合併症の低減などの工夫により、その術式も徐々に変化してきている。本稿ではわれわれが行っている腹式広汎子宮全摘術について手順とポイントを概説する。.
3. 城戸咲、加藤聖子, SLEの増悪, 臨床婦人科産科. 73(4)増刊号:318-23, 2019.04, 妊産褥婦の合併疾患への対処法 内分泌・自己免疫疾患.
4. Minami C, Tsunematsu R, Hiasa K, Egashira K, Kato K, Successful Surgical Treatment for Congenital Vaginal Agenesis Accompanied by Functional Uterus: A Report of Two Cases., Gynecol Minim Invasive Ther. 8(2): 76-9, 10.4103/GMIT.GMIT_124_18, 2019.04, We present two cases of congenital vaginal agenesis with functional uterine corpus, manifesting with periodic lower abdominal pain and hematometra in adolescence. Both patients were successfully treated with the creation of neovagina and neocanal structures to discharge menstrual blood; this may also facilitate the preservation of fertility. Both cases were characterized by degrees of congenital vaginal agenesis, whether short or completely absent, with no communication between the uterine cavity and external genitalia, as confirmed by physical examination and imaging. We surgically reconstructed a neovagina with the modified McIndoe's procedure, using an artificial skin graft, and canalized to the caudal portion of the uterine cavity. Although redilatation of the neocanal was required, no patient suffered severe infection in postoperative course and both now exhibit regular menstruation. Although hysterectomy has classically been the preferred treatment for such cases, recent technical progression enables treatment of such diseases with conservative and minimally invasive surgery, in a safe manner..
5. 詠田真由、甲斐翔太朗、中野嵩大、城戸咲、蜂須賀正紘、日高庸博、藤田恭之、江頭活子、加藤聖子, 総排泄腔遺残術後患者における分娩の1例, 福岡産科婦人科学会雑誌. 42(2): 23-27, 2018.12, 総排泄腔遺残は、女児の尿直腸中隔の形成異常により、尿道、膣、直腸の共通管のみが会陰に開口する疾患である。通常小児期から思春期にかけて外科治療が行われる。今回我々は総排泄腔遺残術後に自然妊娠が成立し、帝王切開分娩に至り、産褥期にも異常を認めなかった一例を経験したので報告する。症例は28歳、初産婦。出生時より総排泄腔遺残と診断され、複数回の手術を受けた。性交障害なく、27歳で自然妊娠が成立した。妊娠経過に異常はなく、軟産道強靭のため、経膣分娩は困難と判断し、妊娠38週に選択的帝王切開術を施行した。開腹時、腹膣内の癒着のため、解剖学的位置関係の同定が困難であった。剥離を進め、周囲臓器を同定し、合併症なく帝王切開術を施行した。術後経過に異常はなく、産褥5日目に児とともに退院した。産後を通して、悪露の排泄障害や手術後の感染徴候はなく経過した。産褥1か月後の診察でも異常を認めなかった。.
6. Morita A , Kido S, Hachisuga M , Nagata H , Hidaka N, Kato K, Twin pregnancy complicated by total placenta previa in a Fontan-palliated patient: A case report., Case Rep Womens Health, 10.1016/j.crwh.2018.e00085, 2018.10, We present a case of a twin pregnancy in a Fontan-palliated woman that was complicated by total placenta previa. The patient was diagnosed with tricuspid atresia type II, and underwent the Fontan operation at 11 years of age. At 32 years of age, she was shown to have a dichorionic diamniotic twin pregnancy. A placenta previa was also noted. At 26 weeks' gestation, she had difficulty breathing, cardiomegaly, and worsening mitral regurgitation. At 29 weeks' gestation, an emergency cesarean section was performed, as the patient had massive genital bleeding. A postoperative cardiac catheterization demonstrated a leak from the lateral tunnel to the atrium, which was considered a cause of hypoxemia during the peripartum period. The cardiac workload in a twin pregnancy is greater, which places a Fontan-palliated patient at increased risk. Careful follow-up monitoring with multidisciplinary expertise is recommended..
7. 横田奈津子、江頭活子、加藤聖子, 特集 産婦人科関連ホルモンの基礎を学びなおす
4.プロゲステロン受容体
, 産科と婦人科. 84(7): 798-803, 2018.06, プロゲステロン受容体(PR)は、核内受容体のうち、ステロイドホルモン受容体スーパーファミリーに属し、PR-AおよびPR-Bの2つのサブタイプが存在する。転写因子として機能し、おもに生殖器、乳腺、脳の中枢に発現し、生殖に重要な役割を果たしている。選択的プロゲステロン受容体修飾薬はわが国では未承認だが、子宮筋腫の治療薬として注目されている。.
8. 吉田祥子、加藤聖子, がん幹細胞研究の展望, 日本臨牀 増刊号 婦人科がん(第2版), 2018.03, 近年、正常組織と同様にがん組織にも幹細胞が存在ることが明らかとなり、難治性がんの原因とされている治療抵抗性、再発などにがん幹細胞が重要な役割を担っていると考えられている。がん幹細胞に対する治療が確立されれば、がんの根治へとつながる可能性がある。本稿ではがん幹細胞の概念とともに、がん幹細胞の治療標的としての現状と今後について述べる。.
9. 東島弘明、藤田恭之、佐藤由佳、城戸咲、加藤聖子, 胎児MRI検査が有用であった Potter sequence の1例, 福岡産科婦人科学会雑誌41(2):9-12, 2017.09, Potter sequenceは、羊水過少、肺低形成を来し予後不良な疾患であることから、その出生前診断は重要である。症例は27歳の初産婦。近医で妊娠19週4日に羊水過少を指摘され当院受診した。初診時の超音波断層法では羊水ポケット、AFIともに0cmであった。腎臓、膀胱は描出困難で、カラードプラ法においても腹部大動脈から分岐する腎動脈を同定できなかった。 Potter sequenceが疑われ、超音波診断の精度を上げるために人工羊水注入を試みたが、穿刺針を留置するスペースを得ることができず、人工羊水注入ができなかった。両側腎無形成の診断のために妊娠21週にMRI検査を施行したが胎児腎臓を確認することはできず、腎無形成に伴うPotter sequenceと診断した。本人、家族が人工妊娠中絶を希望され、妊娠21週4日に320gの男児を娩出した。児の肉眼所見では、折り重なった耳、耳介低位、足間接の拘縮、仙骨部の髄膜瘤を認めた。腹部は陥凹し、腹部超音波断層法では腎臓の描出は困難で、膀胱も認めなかった。剖検の同意は得られず、分娩後の絨毛染色体検査は46,XYの正常核型であった。本症例においては、超音波断層法に加えてMRI検査を行うことが、その周産期管理に有用であった。.
10. 八木 裕史、加藤 聖子, ヒトパピローマウイルスと子宮頸がん, 臨牀と研究. 95(2): 155-158, 2018.02, Harald zur Hausen博士らは, 1983年, 1984年に子宮頸癌の組織から16型, および18型ヒトパピローマウイルス(HPV)のDNAを発見した. その後の大規模な疫学調査や分子生物学的解析の結果, 90%以上の子宮頸癌組織では16型をはじめとする特定のHPV(高リスク型HPV)がコードする遺伝子E6, E7が高発現していることや, E6, E7遺伝子が子宮頸癌の発癌における中心的な役割を果たしていることなどが明らかとなった. HPVによる子宮頸癌の発生機構の解明は, 癌の予防, 治療戦略に大きな変化をもたらし, Harald zur Hausen博士に2008年ノーベル生理学・医学賞が授与された. 本稿では, HPV感染から子宮頸癌に至る分子機構, その分子機構を標的とした子宮頸癌の予防および治療戦略についての最近の知見を概説する..
11. 江頭 活子, 加藤 聖子, 総排泄腔遺残, 産科と婦人科, 2017.06, 総排泄腔遺残は女児にのみ発生する。尿道、膣、直腸が総排泄腔に開き、会陰に総排泄腔のみが開口している。総排泄腔の長さ、その他の要因により症状の重症度は多様である。
小児期には外科手術、その後、排尿、排便のケアが行われるが、思春期以降、子宮・腔留血症、月経困難症などが問題となり、産婦人科での診療が必要となる。その後の性機能の問題、妊娠、出産などに関しては産婦人科が治療の主体となるであろう。
総排泄腔の診断、手術、予後などについて当科で経験した症例を含めて記載した。.
12. 加藤 聖子, 婦人科がんの治療の現状と次世代への展望, 埼玉産科婦人科学会雑誌. 47(1): 27-31, 2017.03, 婦人科がんの治療において最近、新しい流れがみられる。
手術において、低侵襲である腹腔鏡手術が導入され、早期子宮体がんでは保険診療として、子宮頸癌の広汎子宮全摘術は高度先進医療として行われている。また、センチネルリンパ節生検を利用した縮小手術も臨床試験として行われている。子宮頸癌に対しては、妊孕性温存のための子宮頸部摘出術が選択肢の一つとして行われている。化学療法のプロトコール完遂率に影響する悪心・嘔吐に対して、我々は多施設共同研究を行い、中等度催吐性のTC療法において、高度催吐性抗癌剤と同様、アプレピタント・5HT₃受容体拮抗薬・デキサメソゾンの3剤が有効であることを明らかにした。
分子標的治療に重要なのが、バイオマーカーの同定である。我々は、子宮体癌細胞の腫瘍能獲得機構にはRas/Estrogen Receptor/MDM2/p53経路が、子宮体癌幹細胞の形質獲得のためには上皮間葉移行経路が重要であることを明らかにしてきた。最近、卵巣癌において三量体G蛋白Gα₁₂/₁₃が高発現しており、Hippo経路を介して増殖能に関与していることを報告した。
次世代への展望として、既存の抗がん剤や分子標的薬の耐性克服のための新規治療薬の開発が重要である。我々は転写因子Y-box protein 1 (YB-1)の発現を阻害する人工核酸YB-1アンチセンスを開発し、前臨床試験を行っている。.
13. 加藤 聖子, なぜ、女性のがんは増加しているのか?, 臨牀と研究 93(6): 769-773, 2016.06, 最近、増加しつつある女性のがんは乳がん、子宮体がん、卵巣がんおよび若年者の子宮頸がんである。子宮頸がんは性交渉により感染するヒトパピローマウイルスが関与することが明らかになっている。また、子宮体がんは、肥満・糖尿病・高血圧などの生活習慣病、乳がんは初産年齢が高い・出産時数が少ないことがリスクであり、初交年齢の若年化・食生活週間の欧米化・少子化・晩産化などの女性のライフスタイルの変化がこれらのがんの増加に関与していると言われている。本稿では、これらのがんの増加の理由についてメカニズムを含めて考察する。.
14. 加藤 聖子, 子宮内膜幹細胞と生殖医療, HORMONE FRONTIER IN GYNECOLOGY 23(2): 55-59, 2016.06, 幹細胞は自分と同じ細胞をつくる能力(自己複製能)とさまざまな細胞に分化する能力(多分化能)をもつ細胞と定義されている。子宮内膜は月経周期ごとに増殖と剥離を繰り返す再生能力の高い組織であり、世界中でさまざまな手法を用いて子宮内膜腺上皮や間質の幹細胞の同定・分離が試みられてきた。
本稿では、side population(SP)細胞や子宮内膜間葉系幹細胞の研究成果を中心に、その生物学的特性やマーカー、生殖医療への応用・展開について概説する。.
15. 加藤 聖子, 子宮体癌の発生・進展機構の解明と新規治療法の開発 がん幹細胞の観点から, 日本産科婦人科学会雑誌, 2015.09.
16. 米田智子, 加藤聖子, 和氣徳夫, ゲノム研究最前線―疾患ゲノム研究の現状と展望―産婦人科領域, 日本臨床社, 2009.06.
17. 加藤聖子, ここまできた分子標的治療 子宮体癌, 臨床婦人科産科, 2007.06.
主要学会発表等
1. 加藤聖子, 産婦人科をめぐる最新の話題, 山口産科婦人科学会・山口県産科婦人科医会特別講演, 2019.06, 近年、産婦人科医療をめぐっては、生殖内分泌・周産期・婦人科腫瘍のいずれの分野でも様々な課題がでてきている。まずは晩婚化・晩産化に伴う妊孕性低下があげられる。多くは卵の老化が原因と考えられているが、生殖補助医療の現場では受精卵の質は問題なくても、35歳を過ぎると妊娠率が低下することはよく知られた事実である。我々は着床の場である子宮内膜に着目した。子宮内膜の老化に焦点をあて、マウスを用いた加齢により変化する遺伝子同定の試みや、ヒト臨床検体を用いた着床不全の病態への子宮内膜の関与の研究を紹介する。晩産化に伴うもう一つの問題は合併症妊娠の増加である。この中でも妊娠高血圧症候群は全妊娠の5%をしめ、重篤になると母児共に生命を危うくする合併症を併発する。胎盤の形成不全が原因と考えられているが不明な点も多くその病態の解明は重要である。我々は妊娠高血圧症候群と正常妊娠の胎盤を用いて網羅的発現遺伝子解析や免疫染色を行い、妊娠高血圧症の胎盤は硬度が高く病理学的には線維化が起こっていることを明らかにした。本講演ではそのメカニズムを解析した研究を紹介する。また、婦人科腫瘍の分野では、若年子宮頸癌の増加が社会的問題である。妊孕性を温存する手術として現在多くの施設で子宮頸部摘出術(トラケレクトミー)が行われている。当教室ではこれまでに約200例のトラケレクトミーを経験している。我々は、予後、不妊治療の実際、妊娠管理の問題点、術後合併症などを解析し報告してきたので紹介する。以上、産婦人科医療をめぐる問題を、晩婚化・晩産化・若年子宮頸癌の増加を例に基礎研究・臨床研究の視点より考えていく。.
2. Kaoru Okugawa, Shusaku Inoue, Keisuke Kodama, Shinichiro Yamaguchi, Hironori Kenjo, Hiroshi Yagi, Tatsuhiro Ohgami, Masafumi Yasunaga, Ichirou Onoyama, Eisuke Kaneki, Hideaki Yahata, Kiyoko Kato, Safety evaluation of abdominal trachelectomy in patients with cervical cancer with tumors ≥2 cm:A single-institution, retrospective analysis, 第71回日本産科婦人科学会学術講演会, 2019.04, Purpose:For oncologic safety, vaginal radical trachelectomy is generally limited to patients with cervical cancer < 2 cm. However, inclusion criteria for abdominal trachelectomy are unclear. Our aim was to evaluate the safety of abdominal trachelectomy for cervical cancer 2 cm. Methods:Our institutional review board approved this clinical study, and informed consent was obtained from each patient. We began performing abdominal trachelectomy at our institution in 2005. The preoperative criteria consisted primarily of(1)stage IB1 or less advanced squamous cell cancer 3 cm(including stage IIA1 with slight vaginal involvement);or(2)adenocarcinoma/adenosquamous carcinoma 2 cm. If a positive sentinel lymph node or cervical margin was diagnosed intraoperatively by frozen section, trachelectomy was converted to hysterectomy. The medical records of these patients were reviewed retrospectively. Results:We attempted trachelectomy in 217 patients. Among 142 patients with tumors < 2 cm, trachelectomy was successful in 127, none of whom developed recurrence. Altogether, 29 pregnancies were achieved in 22 women with 15 infants delivered. For 75 patients with tumors 2 cm, trachelectomy was successful in 61. Among them, two developed recurrence, eight pregnancies were achieved in five women with five infants delivered. For 29 patients who could not undergo trachelectomy, 14 had tumors 2 cm, and 22 had vascular permeation.
Considerations & Conclusions:Intraoperative frozen sections of sentinel lymph nodes and cervical margins allowed us to perform trachelectomy safely even in patients with tumors 2 cm..
3. Hiroshi Yagi、Ichirou Onoyama、Kazuo Asanoma、Masafumi Yasunaga、Keisuke Kodama、Shusaku Inoue、Shinichiro Yamaguchi、Tatsuhiro Ohgami、Eisuke Kaneki、Kaoru Okugawa、Hideaki Yahata、Kiyoko Kato, GEP oncogene induces epithelial-mesenchymal transition in ovarian cancer through LATS1 proteolysis, 第71回日本産科婦人科学会学術講演会, 2019.04, Purpose:Cancer cells can co-opt the activity of G protein-coupled receptors(GPCRs)for their progression. Recent studies have revealed that overexpression of, or activating mutations in, GPCR-linked heterotrimeric G proteins, including GNAS, GNAQ, GNA12 and GNA13, play critical roles in the progression of human cancers. Among them, G α 13, encoded by the GEP oncogene, GNA13, has been implicated in the progression of various human cancers. However, our understanding of the function of G α 13 in cancer progression remains limited because of the lack of experimental systems that enable the
exclusive examination of G α 13 signaling. Here, we evaluated downstream targets of GEP oncogene that are implicated in ovarian cancer progression. Methods:To examine the effect of G α 13 activation on ovarian cancer cells, we employed constitutively active mutant of G α 13(G α 13QL)or synthetic biology approach using a mutant GPCR and chimeric G protein. Morphological change, protein expression profiles and intracellular signaling pathways were analyzed.
Results:Regarding both in cell morphology and protein expression profile, sustained activation of G α 13 induced epithelial-mesenchymal transition in ovarian cancer cells through down regulation of LATS1, a critical component of the Hippo signaling pathway. A synthetic biology approach revealed that G α 13-regulated phosphorylation of LATS1 at Serine 909 within its activation loop induced recruitment of the E3 ubiquitin ligase, ITCH, to trigger LATS1 degradation.
Considerations & Conclusions:Our findings uncover novel mechanisms through which G α 13 activation induces dysregulation of the Hippo signaling pathway, leading to aggressive cancer phenotypes, thereby identifying a potential target for preventing metastatic spread of ovarian cancer..
4. 加藤 聖子, 性分化疾患の治療, 第71回日本産科婦人科学会学術講演会, 2019.04, 性分化疾患の治療は、出生直後から小児期・思春期を経て成人期まで生涯にわたり続く。本講演では本疾患の内科的・外科的治療法を解説する。ターナー症候群は約2000人に1人の割合で発症し、低身長に加え心疾患などを併発し、小児科で成長ホルモン投与や合併症のフォローを受けている。産婦人科では身長が140cmに達した後、段階的にエストロゲンを投与し子宮の成熟を促し、骨粗鬆症の予防をする。完全型の表現型は女性型で、無月経で来院することが多い。精巣の腫瘍化、悪性化のリスクがあり、青年期に摘出術を行い、その後はエストロゲン補充療法や必要に応じて造腟術を行う。先天性副腎皮質過形成は常染色体劣性遺伝を示し、90%が21-水酸化酵素欠損症である。外性器の以上(陰核肥大・腟開口部狭窄)がみられ、陰核形成や腟形成が施行される。適切なグルココルチコイドが投与されていれば妊娠・分娩も可能であり、内分泌専門医との連携が必要である。総排泄腔遺残症は出生5万人に1人という稀な疾患である。尿道・腟・直腸が共通管に開き、会陰には総排泄口のみが開口している。幼児期に肛門形成・腟形成をされるが、腟狭窄のため思春期以降、子宮・腟留血症、月経困難症などが問題となり産婦人科の関与が必要になる。生命予後が改善され、結婚し挙児希望症例には排便・排尿機能だけでなく生殖機能の管理が重要で、月経血流出路や性交障害改善のため、腟拡張術や外陰形成術を行う。以上のように、小児科・小児外科・産婦人科・泌尿器科・内科・形成外科の他、心理的なケア・サポートが必要な場合も多く、遺伝子異常を伴う場合は遺伝カウンセリングを含む多職種で行う必要がある。.
5. 加藤聖子, 産婦人科医療をめぐる問題を基礎・臨床研究から考える, 慈恵医大産婦人科教室同窓会(妙手会)総会 学術講演会, 2018.12, 近年、産婦人科医療をめぐっては、生殖内分泌・周産期・婦人科腫瘍のいずれの分野でも様々な課題がでてきている。まずは晩婚化・晩産化に伴う妊孕性低下があげられる。多くは卵の老化が原因と考えられているが、生殖補助医療の現場では受精卵の質は問題なくても、35歳を過ぎると妊娠率が低下することはよく知られた事実である。我々は着床の場である子宮内膜に着目した。子宮内膜の老化に焦点をあて、マウスを用いた加齢により変化する遺伝子同定の試みや、ヒト臨床検体を用いた着床不全の病態への子宮内膜の関与の研究を紹介する。晩産化に伴うもう一つの問題は合併症妊娠の増加である。この中でも妊娠高血圧症候群は全妊娠の5%をしめ、重篤になると母児共に生命を危うくする合併症を併発する。胎盤の形成不全が原因と考えられているが不明な点も多くその病態の解明は重要である。我々は妊娠高血圧症候群と正常妊娠の胎盤を用いて網羅的発現遺伝子解析や免疫染色を行い、妊娠高血圧症の胎盤は硬度が高く病理学的には線維化が起こっていることを明らかにした。本講演ではそのメカニズムを解析した研究を紹介する。また、婦人科腫瘍の分野では、若年子宮頸癌の増加が社会的問題である。妊孕性を温存する手術として現在多くの施設で子宮頸部摘出術(トラケレクトミー)が行われている。当教室ではこれまでに200例以上のトラケレクトミーを経験している。我々は、予後、不妊治療の実際、妊娠管理の問題点、術後合併症などを解析し報告してきたので紹介する。以上、産婦人科医療をめぐる問題を、晩婚化・晩産化・若年子宮頸癌の増加を例に基礎研究・臨床研究の視点より考えていく。.
6. 矢幡秀昭、貴島雅子、井上修作、小玉敬亮、山口真一郎、権丈洋徳、八木裕史、安永昌史、大神達寛、小野山一郎、兼城英輔、奥川馨、加藤聖子, 早期子宮頸癌におけるセンチネルナビケーション手術の予後および合併症に関する解析, 第56回日本癌治療学会学術集会, 2018.10, background:To evaluate the prognostic outcome and surgical complications in patients with early-stage cervical cancer who underwent sentinel node navigation surgery(SNNS) for hysterectomy or trachelectomy. Methods:A total of 139 patients who underwent SNNS using 99m Tc phytate between 2009 and 2015 were evaluated. No further lymph node dissection was performed when intraoperative analysis of the sentinental lymph nodes (SLNs) was negative for metastasis. We compared the surgical complications between the SNNS group and 67 matched patients who underwent pelvic lymph node dissection (PLND) after SLN mapping between 2003 and 2008. We also examined the clinical outcomes in the SNNS group. Results: The mean number of detected SLNs was 2.5 per patient. Fourteen of the 139 patients in the SNNS group underwent PLND based on the intraoperative SLN results. The amount of blood loss, the operative time, and the number of perioperative complications were significantly less in the SNNS group than in the matched PLND group. There was no recurrence during a follow-up period ranging from 2 to 88 months(median, 40 months) in the SNNS group. Conclusions: Using SNNS for early-stage cervical cancer is safe and effective and does not increase the recurrence rate. A future multicenter trial is warranted. .
7. 加藤聖子, 婦人科腫瘍におけるゲノム医療の展開, 平成30年度第2回島根産科婦人科学会学術集会, 2018.09.
8. 加藤聖子, 婦人科腫瘍におけるゲノム医療の展開, 第145回東北連合産科婦人科学会総会・学術講演会, 2018.06.
9. 加藤 聖子, 女性ホルモンの発癌機構への関与~子宮体癌を中心に, 第91回日本内分泌学会学術総会, 2018.04.
10. 詠田真由、日浅佳奈、河村圭子、河村英彦、横田奈津子、江頭活子、加藤聖子、安田浩, 総排泄腔遺残術後の患者に対し、外陰形成術を施行した2症例, 第156回福岡産科婦人科学会, 2018.01.
11. 加藤 聖子, 子宮内膜と子宮体がんの幹細胞, 第1回がん三次元培養研究会, 2017.12, 近年、様々な成体組織や癌組織に自己複製能と多分化能を持つ幹細胞の存在が報告されている。組織および癌組織の幹細胞を同定する手段として、DNA結合色素Hoechst33342で細胞を染色し、UVで励起させた際、450/600nmの波長を暗く発現している細胞集団side population(以下SP細胞)を分離する方法が用いられている。
 子宮体癌は近年増加しており約8割はestrogenエストロゲン依存性である。我々は、正常子宮内膜にSP細胞が存在することを明らかにした。このSP細胞は、長期増殖能をもち、3次元培養にて腺管上皮様構造に分化するなど幹細胞様の性質を示した。ラット子宮内膜より分離したSP細胞とnon-SP細胞に変異性KRAS遺伝子を導入したところ、SP細胞に導入した時のみ継代的な腫瘍形成能を獲得し、Estrogen Receptor機能の亢進もみとめられた。この結果は子宮体癌発生機構への正常子宮内膜幹細胞の関与を示唆している。
 次に子宮体癌細胞株Hec1細胞からSP細胞を分離し、その生物学的特性を解析し、分化マーカー発現低下、長期増殖能、自己複製能、運動能亢進、造腫瘍能亢進に加え、腫瘍細胞だけではなく間質細胞への分化能を示すなどがん幹細胞様の性質を持つことを明らかにした。平滑筋への分化条件下で3次元培養を行ったところ、SP細胞はα-Smooth muscle actinを発現する細胞に分化した。SP細胞はnon-SP細胞に比べて、マイクロアレイのパスウェイ解析にて上皮間葉移行(EMT)に関与するシグナル伝達経路を構成する遺伝子群の発現が亢進していた。EMT関連遺伝子であるSPARC,fibtonectinの発現と運動能の亢進は正の相関を示した。現在、EMT関連遺伝子発現の細胞生物学的影響を解析中である。.
12. Onoyama I, Sonoda K, Mechael,R Green, Kato K, Poster Exhibition; Oncogenic BRAF promotes global DNA hypomethylation via upregulation of DNA demethylase TET3 level
, The 5th Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO), 2017.11, Although a hallmark of human cancer genomes is global DNA hypomethylation accompanied by focal DNA hypermethylation, the basis of DNA hypomethylation remains to be determined. We investigated the mechanisms and
the biological significance of DNA hypomethylation in the process of carcinogenesis.
With the use of embryonic fibroblasts from oncogenic BrafV600E knock-in mice, we found that the expression of BrafV600E is sufficient to promote global DNA hypomethylation. DNA demethylase Tet3 is maintained at low level resulting from ubiquitination and degradation by SCF-type ubiquitin ligase SCF Fbxw7 in wild type mice. BrafV600E increased Tet3 protein levels via inhibition of Gsk3β、an inhibitor of Tet3 phosphorylation that is required for SCF Fbxw7-mediated ubiquitination. Consistent with these results, we found that the levels of TET3 and 5-hydroxymethylcytosine, an intermediate product of 5-methylcytosine demethylation, increased in human colorectal adenomas containing BRAFV600E. Conversely, we showed that knockdown of Tet3 decreased BrafV600E-induced lung tumorigenesis in mice.
Our results elucidate a mechanism of global DNA hypomethylation promoted by oncogenic BRAF and establish an essential role for TET3 at an early stage of oncogenesis.
.
13. Kodama K, Sonoda K, Kijima M, Yamaguchi S, Yagi H, Yasunaga M, Ogami T, Onoyama I, Kaneki E, Okugawa K, Kato K, Retrospective analysis of 14 leiomyosarcoma cases treated in our institution, The 5th Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO), 2017.11, Background and Objectives: Uterine leiomyosarcoma is a highly aggresive and lethal disease. This malignancy remains the most common type of uterine sarcoma, affecting approximately 0.4/100,000 women per year. Our aim is to assess the treatment and prognosis of leiomysarcoma patients
Methods: We retrospectively analyzed the clinicopathological variables and prognosis in 14 patients who were treated at our institution.
Results: A total of 14 patients were trated at our institution between January 2008 and July 2017. The median patients age and observation period were 63 years(range, 35-83 years) and 17months(range, 5-75 months), respectively. The largest group of patients by tumor stage was IB(IB, n=8; IIB, n=1; IVB, n=3); the largest group by historogical subtype was conventional leiomyosarcoma(conventional, n=11; myxoid, n=2; epithelioid, n=1). We performed total abdominal hysterectomy and bilateral salpingo-oophorectomy for all patients with additional operative procedure(e.g. tumor resection, lymphadenectomy) if necessary. Twelve patients received adjuvant chemotherapy consisting of docetaxel and gemcitabine. Ten patients experienced recurrence and multidisciplinary therapy was performed including tumor resection, chemotherapy, radiation and molecular-targetted agents. In observation period so far, 11 patients are alive (without disease, n=5; with disease, n=6).
Conclusions: Although uterine leiomyosarcoma is a lethal tumor, multidisciplinary therapy might be useful to control disease after recurrence. .
14. 兼城 英輔, 貴島 雅子, 小玉 敬亮, 山口 真一郎, 八木 裕史, 大神 達寛, 安永 昌史, 小野山 一郎, 権丈 洋徳, 奥川 馨, 矢幡 秀昭, 園田 顕三, 加藤 聖子, 胞状奇胎の搔爬術 - 再搔爬は必要?, 第35回日本絨毛性疾患研究会, 2017.11, 本邦では胞状奇胎除去術後の再搔爬が多くの施設で行われてきた。絨毛性疾患取り扱い規約ー第3版ーでも、「画像検査で胞状奇胎の遺残が疑われる場合は1週間後に再度子宮内容搔爬を施行し、胞状奇胎の遺残がないことを組織学的に確認することが望ましい」と記載されている。一方で、海外では胞状奇胎に対して通常1回の搔爬のみ行われている。奇胎除去後に続発性症を発症した場合に再搔爬は不要とする報告は存在するが、本邦で行われている胞状奇胎除去術より1週間目での再搔爬の有用性について検討した報告はない。当科で胞状奇胎除去術を施行した症例の後方視的解析をもとに再搔爬の必要性を検討した。.
15. 兼城 英輔, 奥川 馨, 矢幡 秀昭, 園田 顕三, 加来 恒壽, 加藤 聖子, 絨毛性疾患の病理診断と細胞像, 第56回日本臨床細胞学会秋期大会, 2017.11.
16. 加藤 聖子、小野山一郎、大神達寛、園田顕三, 子宮体癌発癌機構研究の新たな展開と分子標的治療薬の展望, 第55回日本癌治療学会学術集会, 2017.10.
17. 加藤 雅也, 小野山 一郎, 小玉 敬亮, 八木 裕史, 淺野間 和夫, 園田 顕三, 加藤 聖子, 子宮体癌におけるDUSP6 の発現は癌幹細胞形質維持に関わる, 第76回日本癌学会学術総会, 2017.09.
18. Kato K, Study of endometrial cell aging, The 22nd Seoul International Symposium, 2017.09.
19. 加藤 聖子, 産婦人科における幹細胞研究, 第4回新潟産婦人科シンポジウム, 2017.09.
20. 加藤 聖子, 子宮内膜をめぐる話題, 第63回愛媛県産婦人科医会学術集談会・第29回愛媛県産婦人科医会臨床集談会, 2017.05.
21. Kitade S, Onoyama I, Yagi H, Yoshida S, Kato M, Tsunematsu R, Asanoma K, Sonoda K, Kobayashi H, Hata K, Kiyoko Kato, FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors.
, 第69回日本産科婦人科学会学術講演会, 2017.04, FBXW7 is a ubiquitin ligase that mediates ubiquitylation of oncoproteins, such as c-Myc, cyclin E, Notch and c-Jun. FBXW7 is a known tumor-suppressor gene, and mutations in FBXW7 have been reported in various human malignancies. In this study, we examined the sequences of the FBXW7 and p53 genes in 57 ovarian cancer clinical samples. Interestingly, we found no FBXW7 mutations associated with amino acid changes. We also investigated FBXW7 expression levels in 126 epithelial ovarian tumors. FBXW7 expression was negatively correlated with the malignant potential of ovarian tumors. That is to say, FBXW7 expression levels in ovarian cancer samples were significantly lower than those in borderline and benign tumors (P < 0.01). FBXW7 expression levels in serous carcinoma samples were the lowest among four major histological subtypes. In addition, p53-mutated ovarian cancer samples showed significantly lower levels of FBXW7 expression compared with p53 wild-type cancer samples (P < 0.001). DNA methylation arrays and bisulfite PCR sequencing experiments revealed that 5'-upstream regions of FBXW7 gene in p53-mutated samples were significantly higher methylated compared with those in p53 wild-type samples (P < 0.01). This data indicates that p53 mutations might suppress FBXW7 expression through DNA hypermethylation of FBXW7 5'-upstream regions. Thus, FBXW7 expression was downregulated in ovarian cancers, and was associated with p53 mutations and the DNA methylation status of the 5'-upstream regions of FBXW7..
22. Yagi H, Kodama K, Yasunaga M, Ogami T, Onoyama I, Asanoma K, Sonoda K, Kato K, The pivotal role of LATS1 in ovarian cancer progression.
, 第69回日本産科婦人科学会学術講演会, 2017.04.
23. Kiyoko Kato, Japan Society of Gynecologic Oncology guidelines 2013 for the treatment of uterine body neoplasms., 第54回日本癌治療学会学術総会, 2016.10.
24. 加藤 聖子, 子宮体癌の発生・進展機構の解明と新規治療法の開発―がん幹細胞の観点から―, 第67回日本産科婦人科学会学術講演会, 2015.04.
25. 加藤 聖子, 子宮体癌幹細胞を標的とした分子標的治療の開発, 第73回日本癌学会学術総会, 2014.09.
26. 加藤 聖子, 婦人科がん幹細胞を標的とした新規治療法の開発, 第32回日本ヒト細胞学会学術集会, 2014.08.
27. Hiroshi Yagi, Kenzo Sonoda, Hiroaki Kobayashi, Kiyoko Kato, IS Award Candiate:The role of GEP oncogenes, G12 and G13, in the progression of ovarian cancer.
, 第66回日本産科婦人科学会学術講演会, 2014.04.
28. KAZUO ASANOMA, Hiroaki Kobayashi, Norio Wake, Kiyoko Kato, Transcriptional factors, DEC1 and DEC2 cooperatively regulate epithelial-to-mesenchymal transition of uterine endometrial cancer cells.
, 第66回日本産科婦人科学会学術講演会, 2014.04.
29. 加藤聖子, 子宮内膜症発生・発癌メカニズムと薬物療法, 宮崎市郡産婦人科医会学術講演会, 2013.10.
30. 加藤聖子, Development of new cancer therapy by targeting endometrial cancer stem cells, 第72回日本癌学会学術総会, 2013.10.
31. 加藤聖子, 子宮内膜・体癌幹細胞の同定と生物学的特性の解析, 第13回日本内分泌学会九州地方会, 2013.08.
32. 加藤聖子, 子宮体がん幹細胞の生物学的特性の解析と新規治療法の開発, 第125回関東連合産科婦人科学会総会・学術総会, 2013.06.
33. 楠木総司, 加藤 聖子, 稲垣徹訓, 岡部瞳, 須賀新, 金田容秀, 寺尾泰久, 竹田省, 子宮体癌幹細胞のマーカーの同定, 第65回日本産科婦人科学会学術講演会, 2013.05.
34. 河野彩子, 加藤聖子, 稲垣徹訓, 楠木総司, 宮田知子, 竹田省, 秦健一郎, がん幹細胞形質獲得関連遺伝子の統合解析, 第65回日本産科婦人科学会学術講演会, 2013.05.
35. 加藤 聖子, 子宮内膜の機能とその異常, 北九州産婦人科医会・八幡産婦人科医会学術講演会, 2013.04.
36. 加藤聖子, 磯部明子, 松下幾恵, 恒松良祐, 岡本加奈子, 内田聡子, 和氣徳夫, ヒト正常子宮内膜stem like cellの同定と解析, 第53回日本生殖医学会総会, 2008.10.
37. Kato K, Wake N, Epithelial to mesenchymal transition is an important phenotype of
endometrial cancer stem-like cells
, 第67回日本癌学会学術総会, 2008.10.
38. 加藤聖子,高尾知佳,大神達寛,山口真一郎,米田智子,田中義弘,和氣徳夫, 子宮体癌細胞のstem like cellの同定と生物学的特性の解析, 第49回日本臨床細胞学会総会(春季大会), 2008.06.
39. Kiyoko Kato, Tomoka Takao, Yoshihiro Tanaka, Tatsuhiro Oogami, Tomoko Yoneda,Norio Wake, Endometrial side population cells show characteristics of cancer stem-like cells, 第60回日本産科婦人科学会学術講演会, 2008.04.
40. Kiyoko Kato,Norio Wake, Endometrial cancer side population cells show the phenotype of cancer stem-like cell, 第66回日本癌学会学術総会, 2007.10.
41. 加藤聖子,大神達寛,山口真一郎,米田智子,浅野間和夫,和氣徳夫, 子宮体癌細胞のstem like cellの同定と生物学的特性の解析
, 第59回日本産科婦人科学会学術講演会, 2007.04.
42. 加藤聖子, 子宮体癌細胞のside population細胞の解析, 第65回日本癌学会学術総会, 2006.09.
43. 加藤聖子, 子宮内膜発癌機構におけるstem-like-cellの関与, 子宮内膜疾患研究会, 2006.05.
44. 大神達寛、加藤聖子、山口真一郎、浅野間和夫、和氣徳夫, 婦人科癌細胞に対するMithramycin Aの増殖抑制効果, 第58回日本産科婦人科学会学術講演会, 2006.04.
45. 加藤聖子, エストロゲン依存性腫瘍の発癌機構の解明と治療法の開発, 第23回日本絨毛性疾患研究会, 2005.10.
46. 加藤聖子、一戸晶元、須賀新、山吉麻子、有馬隆博、和氣徳夫, 子宮内膜・子宮体癌幹細胞の同定, 第57回日本産婦人科学会学術講演会, 2005.04.
特許出願・取得
特許出願件数  1件
特許登録件数  0件
学会活動
所属学会名
日本産科婦人科学会
日本癌学会
日本婦人科腫瘍学会
日本産婦人科乳腺医学会
日本女性栄養・代謝学会(旧:日本産科婦人科栄養・代謝研究会)
婦人科悪性腫瘍研究機構(JGOG)
日本妊娠高血圧症学会
日本臨床細胞学会
日本胎盤学会
日本サイトメトリー学会
日本IVF学会
日本女性医学学会
日本生殖内分泌学会
日本産科婦人科内視鏡学会
日本癌治療学会
日本組織培養学会
日本内分泌学会
日本周産期・新生児医学会
日本産婦人科手術学会
日本血栓止血学会
日本女医会
福岡母性衛生学会
American Society for Biochemistry and Molecular Biology
学協会役員等への就任
2013.06~2019.06, 日本産科婦人科学会, 理事.
2011.06~2012.07, 日本産科婦人科学会, 代議員.
2012.01~2019.12, 日本癌学会, 評議員.
2014.07~2020.07, 日本婦人科腫瘍学会, 理事.
2012.08~2014.06, 日本婦人科腫瘍学会, 代議員.
2014.04~2020.03, 日本産婦人科乳腺医学会, 理事.
2006.04~2014.03, 日本産婦人科乳腺医学会, 評議員.
2012.08~2018.08, 日本産科婦人科栄養・代謝研究会, 理事.
2012.09~2020.03, 日本妊娠高血圧学会, 理事.
2014.04~2020.03, 日本胎盤学会, 理事.
2014.04~2018.03, 日本サイトメトリー学会, 理事.
2015.11~2019.11, 日本女性医学学会, 理事.
2013.10~2015.10, 日本女性医学学会, 代議員.
2017.11~2019.10, 日本女性医学学会, 副理事長.
2015.08~2019.07, 日本癌治療学会, 代議員.
2014.12~2016.10, 日本IVF学会, 理事.
2015.06, Asia and Oceania Federation of Obstetrics and Gynecology.
2015.08, 九州内視鏡下外科手術研究会, 世話人.
2016.02~2020.02, 福岡市性感染症(STD)研究会, 顧問.
2012.10~2019.03, 福岡母性衛生学会, 理事.
2015.04~2019.03, 福岡県産婦人科医会, 理事.
2016.04~2020.03, 産婦人科漢方研究会, 世話人.
2017.04~2018.05, 特定非営利活動法人婦人科がんバイオマーカー研究会, 理事.
2016.07~2021.08, 公益財団法人佐賀国際重粒子線がん治療財団, 九州国際重粒子線がん治療センター重粒子腺がん治療婦人科腫瘍検討班班長.
2018.06~2021.06, 公益財団法人福岡県すこやか健康事業団, 理事.
学会大会・会議・シンポジウム等における役割
2019.08.05~2019.08.05, VTE Forum in 九州, 座長:特別講演.
2019.07.12~2019.07.12, 婦人科癌分子標的治療セミナー, 座長:特別講演2.
2019.07.07~2019.07.07, 第21回産婦人科MEセミナー(西日本), プランナー.
2019.07.06~2019.07.07, 第18回日本婦人科がん分子標的研究会, 座長:特別講演6.
2019.07.04~2019.07.06, 第61回日本婦人科腫瘍学会学術講演会, 座長:口演International Session3 Ovary.
2019.06.13~2019.06.13, 九州産婦人科勉強会, 座長:講演1,2 .
2019.06.07~2019.06.07, HBOC Scientific Exchange Meeting 2019 in Fukuoka, 総合座長.
2019.05.18~2019.05.19, 第76回九州連合産科婦人科学会・第70回九州ブロック産婦人科医会, 座長:ランチョンセミナー.
2019.04.11~2019.04.14, 第71回日本産科婦人科学会学術講演会, Chair:International Session Workshop 7.
2019.04.03~2019.04.03, Ovarian Cancer Symposium in Fukuoka, 座長.
2019.03.16~2019.03.16, 福岡県女性ヘルスケア講演会, 座長:特別講演.
2019.03.07~2019.03.07, 福岡周産期低ホスファターゼ症カンファランス, 座長:教育講演.
2019.03.02~2019.03.03, 第33回日本助産学会学術集会, 座長:教育講演3.
2019.02.22~2019.02.22, 福岡女性医療懇話会, 座長:特別講演.
2019.01.19~2019.01.20, 第40回日本エンドメトリオーシス学会, 座長.
2018.11.10~2018.11.10, 第5回新潟産婦人科シンポジウム, 座長:第2群.
2018.11.03~2018.11.04, 第33回日本女性医学学会学術集会, 座長:会長講演.
2018.11.03~2018.11.04, 第33回日本女性医学学会学術集会, 座長:シンポジウム1 .
2018.10.27~2018.10.27, 第34回日本小児外科学会秋季シンポジウム, 座長 Chairmanship.
2018.10.18~2018.10.19, 第56回日本癌治療学会学術集会, モデレーター:卵巣癌(ポスター発表).
2018.10.13~2018.10.13, Ovarian Cancer Scientific Exchange Meeting 2018, 座長:Session1.
2018.09.27~2018.09.29, 第77回日本癌学会学術総会, 座長:基礎医学者のための臨床講座 婦人科がん.
2018.09.21~2018.09.24, 24thIFPA 2018 Tokyo (International Federation of Placenta Associations), Moderator:Luncheon Seminar 2.
2018.09.14~2018.09.16, 第60回日本婦人科腫瘍学会学術講演会, Chair:Symposium 1.
2018.09.02~2018.09.02, The 29thFUKUOKA INTERNATIIONAL SYMPOSIUM ON PEDIATRIC/MATERNAL-CHILD HEALTH RESEARCH, Chairperson:Guest Lectures.
2018.09.02~2018.09.02, The 29thFUKUOKA INTERNATIIONAL SYMPOSIUM ON PEDIATRIC/MATERNAL-CHILD HEALTH RESEARCH, Chairperson:Session1.
2018.09.02~2018.09.02, The 29thFUKUOKA INTERNATIIONAL SYMPOSIUM ON PEDIATRIC/MATERNAL-CHILD HEALTH RESEARCH, Chairperson (Organized).
2018.08.26~2018.08.26, 第38回産婦人科漢方研究会学術集会, 座長(Chairmanship).
2018.07.24~2018.07.24, リムパーザ発売記念講演会 福岡, 座長(Chairmanship).
2018.07.10~2018.07.10, 婦人科癌分子標的治療セミナー, 座長(Chairmanship).
2018.07.01~2018.07.01, 第27回福岡母性衛生学会学術集会, 座長 (Chairmanship).
2018.07.01~2018.07.01, 第27回福岡母性衛生学会 学術集会, 学会長.
2018.06.29~2018.06.30, 第15回日本婦人科がん会議, 座長 (Chairmanship).
2018.06.21~2018.06.23, 第43回日本外科系連合学会学術集会, 座長 (Chairmanship).
2018.06.14~2018.06.14, 福岡女性医療フォーラム2018, 座長 (Chairmanship).
2018.05.10~2018.05.13, 第70回日本産科婦人科学会学術講演会, 座長 (Chairmanship).
2018.05.08~2018.05.08, 平成30年度第1回福岡県産婦人科医会 福岡ブロック会学術講演会, 座長 (Chairmanship).
2018.04.26~2018.04.28, 第91回日本内分泌学会学術総会, 座長 (Chairmanship).
2018.04.15~2018.04.15, 第75回九州・沖縄生殖医学会, 座長 (Chairmanship).
2018.03.17~2018.03.17, 第23回日本女性医学学会ワークショップ, 座長 (Chairmanship).
2018.03.11~2018.03.11, 第24回日本産婦人科乳腺医学会, 座長.
2018.03.11~2018.03.11, 第24回日本産婦人科乳腺医学会, 学会長.
2018.03.09~2018.03.09, 九州大学産婦人科勉強会, 座長 (Chairmanship).
2017.11.10~2017.11.11, 第27回日本乳癌検診学会学術総会, 座長(Chairmanship).
2018.02.02~2018.02.02, 第20回産婦人科MEセミナー(西日本), プランナー.
2018.02.02~2018.02.02, 第25回福岡生殖医学懇話会, 座長(Chairmanship).
2018.01.26~2018.01.26, 婦人科癌分子標的治療セミナー, 座長(Chairmanship).
2018.01.17~2018.01.17, 福岡がん・生殖医療症例検討会, 座長(Chairmanship).
2017.11.30~2017.12.02, The 5th Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO) , 座長(Chairmanship).
2017.11.24~2017.11.25, 第25回日本胎盤学会学術集会, 座長(Chairmanship).
2017.11.19~2017.11.19, 学術講演会 これからの流産手術を考える-リスク回避と妊孕性の観点から-, 座長(Chairmanship).
2017.11.18~2017.11.19, 第56回日本臨床細胞学会秋期大会, 座長(Chairmanship).
2017.11.06~2017.11.06, VTE連携セミナー, 座長(Chairmanship).
2017.11.04~2017.11.05, 第32回日本女性医学学会学術集会, 座長(Chairmanship).
2017.10.18~2017.10.19, AOGIN 2017 Tokyo Meeting, 座長(Chairmanship).
2017.10.13~2017.10.13, 福岡女性医療懇話会, 座長(Chairmanship).
2017.09.26~2017.09.26, HBOC Scientific Exchange Meeting in Fukuoka, 座長(Chairmanship).
2017.09.22~2017.09.23, 第38回日本妊娠高血圧学会総会・学術講演会, 座長(Chairmanship).
2017.09.15~2017.09.15, 福岡婦人科サルコーマ研究会, 座長(Chairmanship).
2017.08.27~2017.08.27, The 28thFUKUOKA INTERNATIIONAL SYMPOSIUM ON PEDIATRIC/MATERNAL-CHILD HEALTH RESEARCH, 座長(Chairmanship).
2017.07.27~2017.07.29, 第59回日本婦人科腫瘍学会学術講演会, 座長(Chairmanship).
2017.07.04~2017.07.04, 福岡産婦人科勤務医会, 座長(Chairmanship).
2017.06.10~2017.06.11, 第27回日本サイトメトリー学会学術集会, 座長(Chairmanship).
2017.04.21~2017.04.21, 福岡婦人科セミナー, 座長(Chairmanship).
2017.03.17~2017.03.17, 九州大学産婦人科勉強会, 座長(Chairmanship).
2017.03.15~2017.03.15, 福岡女性医療フォーラム2017, 座長(Chairmanship).
2017.01.24~2017.01.24, 婦人科癌分子標的治療セミナー, 座長(Chairmanship).
2017.01.22~2017.01.22, 第154回福岡産科婦人科学会, 座長(Chairmanship).
2016.12.03~2016.12.03, 第3回日本婦人科腫瘍学会研修会, 座長(Chairmanship).
2016.11.25~2016.11.26, 第24回日本胎盤学会学術集会, 座長(Chairmanship).
2016.11.17~2016.11.17, Fukuokaエンドメトリオーシス研究会, 座長(Chairmanship).
2016.11.12~2016.11.13, 第43回日本産婦人科医会学術集会, 座長(Chairmanship).
2016.11.05~2016.11.06, 第31回日本女性医学学会学術集会, 座長(Chairmanship).
2016.10.25~2016.10.25, Scientific Exchage Meeting in 福岡, 座長(Chairmanship).
2016.10.06~2016.10.08, 第75回日本癌学会学術総会, 座長(Chairmanship).
2016.09.25~2016.09.25, 第153回福岡産科婦人科学会, 座長(Chairmanship).
2016.09.04~2016.09.04, 第36回産婦人科漢方研究会学術集会, 座長(Chairmanship).
2016.09.01~2016.09.02, 第40回日本産科婦人科栄養・代謝研究会, 座長(Chairmanship).
2016.08.28~2016.08.28, The 27thFUKUOKA INTERNATIIONAL SYMPOSIUM ON PEDIATRIC/MATERNAL-CHILD HEALTH RESEARCH, 座長(Chairmanship).
2016.07.23~2016.07.24, 第26回日本サイトメトリー学会学術集会, 座長(Chairmanship).
2016.07.19~2016.07.19, 婦人科癌分子標的治療セミナー, 座長(Chairmanship).
2016.07.08~2016.07.10, 第58回日本婦人科腫瘍学会学術講演会, 座長(Chairmanship).
2016.07.05~2016.07.05, 福岡産婦人科勤務医会(火曜会), 座長(Chairmanship).
2016.05.24~2016.05.26, 第53回日本小児外科学会学術集会, 司会(Moderator).
2016.05.21~2016.05.22, 第73回九州連合産科婦人科学会・第67回九州ブロック産婦人科医会, 座長(Chairmanship).
2016.04.21~2016.04.24, 第68回日本産科婦人科学会学術講演会, 座長(Chairmanship).
2016.04.21~2016.04.24, 第68回日本産科婦人科学会学術講演会, 会長特別企画:Stump the Professors~教授陣と知恵くらべ~ :教授陣.
2016.03.10~2016.03.10, 静脈血栓塞栓連携セミナー, 座長(Chairmanship).
2016.03.05~2016.03.06, The 55thAnnual Congress & The 5th International Symposium of Taiwan Association of Obstetrics and Gynecology, 座長(Chairmanship).
2016.02.16~2016.02.16, 福岡産婦人科セミナー, 座長(Chairmanship).
2016.01.29~2016.01.29, 九州大学産婦人科研究会, 座長(Chairmanship).
2016.01.24~2016.01.24, 第152回福岡産科婦人科学会, 座長(Chairmanship).
2016.01.23~2016.01.24, 第37回日本エンドメトリオーシス学会, 座長(Chairmanship).
2015.11.28~2015.11.29, 第38回日本産婦人科手術学会, 座長(Chairmanship).
2015.11.05~2015.11.06, 第33回日本絨毛性疾患研究会, 座長(Chairmanship).
2015.10.08~2015.10.10, 第74回日本癌学会学術総会, 座長(Chairmanship).
2015.10.03~2015.10.03, 第22回遺伝性疾患に関する出生前診断研究会, 座長(Chairmanship).
2015.09.06~2015.09.06, The 26thFUKUOKA INTERNATIIONAL SYMPOSIUM ON PEDIATRIC/MATERNAL-CHILD HEALTH RESEARCH.
2015.09.10~2015.09.12, 第55回日本産科婦人科内視鏡学会学術講演会, 座長(Chairmanship).
2015.08.07~2015.08.09, 第57回日本婦人科腫瘍学会学術講演会, 座長(Chairmanship).
2015.07.10~2015.07.12, 第51回日本周産期・新生児医学会学術集会, 座長(Chairmanship).
2015.07.04~2015.07.04, 第2回卵巣癌分子標的治療セミナー, 座長(Chairmanship).
2015.06.24~2015.06.24, 女性の健康寿命を考える会, 座長(Chairmanship).
2015.06.06~2015.06.07, 第72回九州連合産科婦人科学会・第66回九州ブロック産婦人科医会, 座長(Chairmanship).
2015.03.01~2015.03.01, 第21回日本産科婦人科乳腺医学会, 座長(Chairmanship).
2015.02.21~2015.02.21, 第3回婦人科がんバイオマーカー研究会学術集会, 座長(Chairmanship).
2015.02.12~2015.02.12, 九州大学産婦人科研究会, 座長(Chairmanship).
2015.02.01~2015.02.01, 第150回福岡産科婦人科学会, 座長(Chairmanship).
2014.12.08~2014.12.08, 女性アスリート診療のための講習会, 座長(Chairmanship).
2014.12.06~2014.12.06, 第1回日本婦人科腫瘍学会研修会, 座長(Chairmanship).
2014.12.03~2014.12.03, 九州HPVセミナー2014, 座長(Chairmanship).
2014.12.02~2014.12.02, 福岡産婦人科セミナー, 座長(Chairmanship).
2014.11.21~2014.11.21, 卵巣癌分子標的治療セミナー, 座長(Chairmanship).
2014.10.31~2014.10.31, 第41回福岡周産期懇話会, 座長(Chairmanship).
2014.10.03~2014.10.04, 第22回日本胎盤学会学術集会, 座長(Chairmanship).
2014.09.25~2014.09.27, 第73回日本癌学会学術総会, 座長(Chairmanship).
2014.08.30~2014.08.31, 第32回日本ヒト細胞学会学術集会, 座長(Chairmanship).
2014.07.31~2014.07.31, 福岡産婦人科セミナー, 座長(Chairmanship).
2014.07.17~2014.07.19, 第56回日本婦人科腫瘍学会学術講演会, 座長(Chairmanship).
2014.06.19~2014.06.19, Dinagest研究会, 開会の挨拶.
2014.05.24~2014.05.25, 第71回九州連合産科婦人科学会・第65回九州ブロック産婦人科医会 ワークショップ, 座長(Chairmanship).
2014.04.18~2014.04.20, 第66回日本産科婦人科学会学術講演会 ランチョンセミナー「マイクロ波子宮内膜アブレーションの基礎とoffice gynecology での実際」, 座長(Chairmanship).
2014.04.18~2014.04.20, 第66回日本産科婦人科学会学術講演会 シンポジウム(腫瘍)「難治性卵巣癌の克服を目指して」, 座長(Chairmanship).
2013.08.31~2013.08.31, 第24回福岡国際母子総合研究シンポジウム(FISP/M), 座長(Chairmanship).
2014.02.23~2014.02.23, 第16回産婦人科MEセミナー(西日本), プランナー.
2014.02.22~2014.02.22, 第6回日本ロボット外科学会, 座長(Chairmanship).
2014.02.07~2014.02.08, 日本周産期・新生児医学会学術集会 第32回周産期学シンポジウム, 座長(Chairmanship).
2014.01.25~2014.01.26, 第35回日本エンドメトリオーシス学会, 座長(Chairmanship).
2013.10.25~2013.10.26, 第21回日本胎盤学会学術集会・第31回日本絨毛性疾患研究会, 座長(Chairmanship).
2013.09.27~2013.09.27, 第36回福岡周産期懇話会, 座長(Chairmanship).
2012.09.01~2013.09.01, 第33回産婦人科漢方研究会学術集会, 座長(Chairmanship).
2013.08.29~2013.08.30, 第37回日本産科婦人科栄養・代謝研究会, 座長(Chairmanship).
2013.06.22~2013.06.23, 第23回日本サイトメトリー学会学術集会, 座長(Chairmanship).
2013.05.10~2013.05.12, 第65回日本産科婦人科学会学術講演会, 座長(Chairmanship).
2013.04.19~2013.04.19, 福岡県再発卵巣癌化学療法学術講演会, 座長(Chairmanship).
2008.04, 第60回日本産科婦人科学会学術講演会, 座長(Chairmanship).
2003.06, 日本婦人科腫瘍学会, コメンテーター.
2017.02.26~2017.02.26, 第19回産婦人科MEセミナー, プランナー.
2016.07.23~2016.07.24, 第26回日本サイトメトリー学会学術集会, 学会長.
2016.02.07~2016.02.07, 第18回産婦人科MEセミナー(西日本), プランナー.
2015.10.03~2015.10.03, 第22回遺伝性疾患に関する出生前診断研究会, 学会長.
2015.06.06~2015.06.07, 第72回九州連合産科婦人科学会・第66回九州ブロック産婦人科医会, 会長.
2015.02.21~2015.02.21, 第3回婦人科がんバイオマーカー研究会学術集会, 会長.
2015.02.08~2015.02.08, 第17回産婦人科MEセミナー(西日本), プランナー.
2013.08.31~2013.08.31, 第24回福岡国際母子総合研究シンポジウム(FISPM)・第11回市民公開講座[産科婦人科], 開催.
学会誌・雑誌・著書の編集への参加状況
2019.01, Cancer Science, 国内, 編集委員.
2015.06, The Journal of Obstetrics & Gynecology Research, 国内, Editor-in-Chief.
2015.01, 女性と健康の百科事典(Women and Health 2nd Edition), 国内, 編集幹事.
2012.04, International Journal of Clinical Oncology(IJCO:日本癌治療学会), 国内, 編集委員.
2010.04~2013.03, The Journal of Obstetrics & Gynecology Research(日本産科婦人科学会英文雑誌), 国内, 編集委員.
学術論文等の審査
年度 外国語雑誌査読論文数 日本語雑誌査読論文数 国際会議録査読論文数 国内会議録査読論文数 合計
2015年度      
2014年度      
2013年度      
2008年度      
2003年度      
2002年度      
2001年度      
その他の研究活動
海外渡航状況, 海外での教育研究歴
The Radisson Hotel, Nepal, 2018.06~2018.06.
受賞
高得点演題グットプレゼンテーション賞, 日本産科婦人科学会総会, 2007.04.
婦人科骨粗鬆症研究会学術集会奨励賞, 婦人科骨粗鬆症研究会, 2006.11.
国際ソロプチミストMD奨励賞, 公益財団法人ソロプチミスト日本財団, 1999.05.
日本医師会医学研究助成, 日本医師会, 1998.10.
研究資金
科学研究費補助金の採択状況(文部科学省、日本学術振興会)
2005年度~2007年度, 基盤研究(B), 代表, 子宮体癌の発癌機構の解明と治療法の開発(エストロゲン依存性腫瘍としての性質の解析と癌幹細胞の同定).
科学研究費補助金の採択状況(文部科学省、日本学術振興会以外)
2018年度~2019年度, 厚生労働科学研究費補助金 (厚生労働省), 分担, 小児期から移行期・成人期を包括する希少難治性慢性消化器疾患の医療政策に関する研究.
寄附金の受入状況
2018年度, エーザイ株式会社, 奨学寄附金/研究課題「子宮体癌細胞における細胞外基質蛋白SPARCの機能解析」.
2018年度, あすか製薬株式会社, 学術研究助成費/研究課題「産婦人科病の新規治療法の開発」.
2018年度, 塩野義製薬株式会社, 奨学寄附金/研究課題「 胎盤の線維化に着目した妊娠高血圧症候群の病態解明に関する研究」「子宮内膜の老化に関与する遺伝子の同定」.
2019年度, 武田薬品工業株式会社, 研究支援/研究課題「婦人科がん幹細胞のバイオマーカーの探索と機能解析」.
2018年度, 株式会社ツムラ, 研究助成金/研究課題「卵巣癌の発生機構の解明」.
2018年度, MSD株式会社, 奨学寄附金/研究課題「がん幹細胞維持機構の解明」.
2018年度, 中外製薬株式会社, 奨学寄附金/研究課題「婦人科がん発生機構の解明」.
2018年度, 大鵬薬品工業株式会社, 奨学寄附金/研究課題「子宮体癌におけるDUSP6遺伝子の機能解析」.
2018年度, 公益財団法人日母おぎゃー献金基金, おぎゃー献金研究助成金
「孤発性の重症胎児発育不全とその胎盤におけるミトコンドリア異常との関係に関する研究」.
2017年度, あすか製薬株式会社, 研究助成金/「婦人科がんの病態解明・治療法の開発」.
2017年度, 塩野義製薬株式会社, 奨学寄附金/研究課題「妊娠高血圧症候群の病態解明に関する研究」「着床不全の病態解明に関する研究」.
2017年度, 武田薬品工業株式会社, 研究支援/研究課題「婦人科がん幹細胞同定・分離の試み」.
2017年度, 第一三共株式会社, 奨学寄附金/研究課題「婦人科悪性腫瘍周術期における静脈血栓症とD dimer値およびプロテインS活性の関連に関する研究」.
2017年度, MSD株式会社, 奨学寄附金/研究課題「がん幹細胞獲得に関与する遺伝子の同定」.
2017年度, エーザイ株式会社, 奨学寄附金/研究課題「子宮体がん幹細胞同定・分離の試み」
.
2017年度, 協和発酵キリン株式会社, 奨学寄附金/研究課題「がん幹細胞の分離法の開発」.
2017年度, 株式会社ツムラ, 研究助成金/研究課題「卵巣癌の発生機構の解明」.
2017年度, 中外製薬株式会社, 奨学寄附金/研究課題「婦人科がんの発生・進展機構の解明」.
2016年度, 科研製薬株式会社, 奨学寄附金.
2016年度, 塩野義製薬株式会社, 奨学寄附金.
2016年度, 日本イーライリリー株式会社, 奨学寄附金.
2016年度, 武田薬品工業株式会社, 奨学寄附金.
2016年度, MSD株式会社, 奨学寄附金.
2016年度, バイエル薬品株式会社, 奨学寄附金.
2016年度, 中外製薬株式会社, 奨学寄附金.
2016年度, 株式会社ツムラ, 奨学寄附金.
2015年度, 小野薬品工業株式会社, 寄附金「子宮内膜幹細胞と着床との関連」.
2015年度, 塩野義製薬株式会社, 寄附金.
2015年度, 株式会社ツムラ, 寄附金.
2015年度, MSD株式会社, 奨学寄付(学術研究支援)「子宮体がん幹細胞自己複製能の分子機構の解明」.
2015年度, 中外製薬株式会社, 寄附金・研究活動への支援「婦人科がんの進展機構に関する基礎的研究活動」.
2015年度, あすか製薬株式会社, 奨学寄附金.
2015年度, シーメンス・ジャパン株式会社, 奨学寄附金「VTによる胎盤の硬さと発育の相関に関する研究」.
2014年度, 武田薬品工業株式会社, 奨学寄附金「婦人科腫瘍発生機序の解明」.
2014年度, 塩野義製薬株式会社, 寄附金「ターゲット・プロテオーム解析による子宮体癌治療標的分子の同定」.
2014年度, 中外製薬株式会社, 奨学寄附「婦人科がん幹細胞の生物学的特性の解析」.
2014年度, 日本イーライリリー株式会社, 教育・研究助成「子宮体癌細胞の生物学的特性における細胞外基質蛋白SPARCの役割の解析」.
2014年度, 株式会社ツムラ, 寄附金「卵巣癌の発生機構の解明」.
2014年度, あすか製薬株式会社, 奨学寄附金.
2014年度, エーザイ株式会社, 寄附金.
2014年度, ハーゼスト株式会社, 寄附金.
2014年度, 科研製薬株式会社, 寄附金.
2014年度, サノフィ株式会社, 寄附金「婦人科がん幹細胞を標的とした治療開発」.
学内資金・基金等への採択状況
2016年度~2021年度, 運営費交付金・機能強化経費, 代表, 「アジア地域における受胎成長発達医学の高度先端医療・先制医療開発及びグローバル人材育成」.

九大関連コンテンツ

pure2017年10月2日から、「九州大学研究者情報」を補完するデータベースとして、Elsevier社の「Pure」による研究業績の公開を開始しました。
 
 
九州大学知的財産本部「九州大学Seeds集」